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ABSTRACT OF THE DISSERTATION
MnTE-2-PyP and Radiation in a Prostate Cancer Model: Implications for Radiotherapy
by
Adeola Y. Makinde
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, June 2009
Dr. Daila S. Gridley, Chairperson

A major limitation of successful radiation therapy in cancer treatment is the
increase in normal tissue damage as higher doses are used to achieve greater tumor
destruction. Radiation dose optimization in cancer therapy requires achieving maximum
tumor destruction with minimal damage to normal tissue Antioxidants have been shown
to protect normal tissues against radiation damage, as radiation-induced tissue damage
results predominantly from reactive oxygen species that directly damage cellular
components. However, for effective use as normal tissue radioprotectants in radiotherapy,
these antioxidants must not protect the tumors. Mn (III) tetrakis (N-ethylpyridinium-2-yl)
porphyrin (MnTE-2-PyP) is a metalloporphyrin antioxidant that has been shown to have
radioprotective properties in normal tissue. The major objective of this project was to
evaluate the effects of MnTE-2-PyP on prostate cancer response to radiation and to
explore mechanisms responsible for the observed effects. Our results showed that
radiation significantly slowed tumor progression and addition of MnTE-2-PyP dis not
significantly alter tumor growth. However, the evaluation of cytokines in spleen, plasma
and tumors suggest that administration of MnTE-2-PyP together with radiotherapy may
enhance anti-tumor immune responsiveness and decrease the risk for radiation-induced
normal tissue toxicities. Assessment of the effects of Mn-TE-2-PyP on radiation response

xvn

in human prostate cancer cell lines showed that drug did not protect PCa cells against
radiation. In addition, in LNCaP cells, a dose-dependent decrease in DNA synthesis and
cell viability was observed with drug treatment. The clinical relevance of this cell line
makes it noteworthy, as they are a close representative of prostate cancer that would be
treated with radiation therapy in patients. Overall, it was demonstrated that the MnTE-2PyP does not protect prostate tumors against radiation damage and is not toxic under the
conditions used. In addition, the drug-induced enhancement of certain immune
parameters suggests that MnTE-2-PyP may be beneficial not only as a normal tissue
radioprotectant, but also as a facilitator of antitumor immunity. This study enhances the
clinical relevance of antioxidant metalloporphyrins and potentially contributes towards
improvement of cancer treatment and radiotherapy.
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CHAPTER ONE
INTRODUCTION
Prostate Cancer

Incidence
Prostate cancer, PCa, is one of the major health problems in the United States and
the rest of the western world. It is the second most common cancer and the third leading
cause of cancer-related deaths in American men. In 2008, the American Cancer Society
(ACS) estimated that prostate cancer accounts for about 25% of all cancers in men
(Jemal, et ah, 2008; Zelefsky, et ah, 2006a). Prostate cancer, otherwise known as prostate
adenocarcinoma, generally refers to malignancy of prostate epithelial cells. Although
there are other types of PCa, prostate adenocarcinoma accounts for over 99% all PCa
cases and therefore is clinically referred to as PCa. Prostatic intraepithelial neoplasia
(PIN) is popularly suggested to be the precursor lesion for prostate adenocarcinoma; in
this condition, there are changes in the appearance, size and shape of prostate gland cells.
These changes are classified into either low or high grade, depending on the degree of
abnormality; grade is highly predictive for prostate adenocarcinoma (Soares, Shibata,
Green, & Jorcyk, 2002; Zelefsky, et ah, 2006a). Detectable changes begin to appear in a
small percentage of men in their 20s, but almost half of the male population has PIN by
age 50. Men diagnosed with high-grade PIN, have a 30% to 50% chance of developing
PCa. Although there is increasing evidence suggesting that PIN is the precursor to
prostate adenocarcinoma, little is known about the molecular biology of PIN and what
1

determines whether PIN lesions will transition into invasive carcinomas (Soares, et ah,
2002).

Risk Factors
Age is well accepted to be the greatest risk factor for developing the disease, since
it is most commonly found in older men, age >50 years. Clinicians believe that most men
will develop PCa in the course of their lives, but because it is generally a slow growing
cancer, it is asymptomatic and most men will die of other causes before it has an impact
on their lives. Research has shown that only a few men who died in their 30s had PCa but
the figures increase with age; 70% to 90% of the men who died at age 80 or older had
PCa. While most PCa are slow growing, some can grow and spread quickly. Increased
research and effort to understand the disease over the past two decades has, however, led
to significant advances in diagnosis and treatment, resulting in decreased morbidity and
mortality of patients (McPhaul, 2008).
Race and nationality have also been recognized as major risks factor for prostate
cancer. African-American men are reported to have the highest incidence, followed by
white men and Hispanic/Latino men; lowest incidence is in Asian-American men. North
America, northwestern Europe, Australia and the Caribbean Islands have the highest PCa
incidence rates. Other possible factors include family history/genes, stress, diet, exercise,
presence of infections and prostatitis (inflammation of prostate gland) (Jemal, et al.,
2008).
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Diagnosis
Effective means of diagnosing the disease consist of Prostate-Specific Antigen
(PSA; also referred to as human kallikrein 3) screening, Digital Rectal Examination
(DRE) and prostate biopsy. PSA is a serine protease produced by the prostate gland and
elevated blood levels are often associated with both localized and metastatic prostate
cancer. Although PSA screening is currently a main PCa diagnostic tool, further testing is
often required for confirmation because elevated levels can also be indicative of benign
prostatic hyperplasia (BPH; also sometimes referred to as benign prostatic hypertrophy)
or prostatitis. DRE is a physical inspection of the prostate for lumps and abnormalities in
the size, shape and texture of the prostate. Generally, if the PCa can be felt on DRE, the
disease is likely to be more advanced (Rubin, et ah, 2003; Thompson, et ah, 2003). A
prostate biopsy is a more invasive evaluation but it can more completely and accurately
confirm a PCa diagnosis. It involves removal of small pieces of the prostate for
evaluation of microscopic features that are used to assign a Gleason score.
Staging is the single most important prognostic factor in evaluating PCa and
determining treatment. The Gleason score is the most common method of grading. It is
used to grade prostate cancer into stages, with scores ranging from 2 to 10, where higher
Gleason scores indicate more aggressive tumors and worse prognosis. The scoring system
takes into account the size of the tumor, spread to regional lymph nodes and presence of
distant metastasis. The stage 1 and 2 tumors are local to the prostate and surrounding
tissue. These primary tumors are typically androgen dependent. Androgens are male
hormones such as testosterone that are needed for prostate glands to function normally.
Development of androgen independence is often associated with stages 3 and 4, which
are indicative of increased risk for cancer aggressiveness, progression and metastasis to
3

other parts of the body such as the lymph nodes and bone (Jones & Koeneman, 2008;
Mendenhall, Henderson, & Mendenhall, 2008; Nilsson, Norlen, & Widmark, 2004;
Thompson, et ah, 2003).

Prostate Cancer Therapy
Recent advances in the understanding of cancer have provided vast opportunities
for the development of novel therapies. Cancer is a heterogeneous disease and its
existence is significantly dependent on its interaction with the host microenvironment.
Examples of such interactions include immune cells (such as inflammatory and bonemarrow derived cells) recruited to site of tumor, presence of reactive oxygen species
(ROS), changing pH, circulating hormone concentrations and stress conditions such as
hypoxia in the tumor microenvironment. The microenvironment, coupled with genetic
modifications in the characteristics of tumors, determines the rate of progression and
metastasis. One of the focal points of cancer therapy is to modify these
microenvironments in ways that would be detrimental to the tumor cells. Current cancer
treatments include hormone therapy, chemotherapy, prostatectomy and radiation therapy.
Gene therapy and immunotherapy are also under investigation in clinical trials
(http://www.cancer.gov/clinicaltrials). The objective of recent developing therapies target
combination treatment regimens, with a majority including radiation therapy.

Hormone Therapy
Development of the prostate is dependent on androgens (such as testosterone);
growth continues until adulthood and is maintained in the presence of these hormones. In
its early stages, PCa shares this androgen dependence with non-malignant prostate tissue
4

and thus hormone withdrawal and inhibition of androgen signal transduction can inhibit
proliferation and induce cell death in tumors. However, it is well known that PCa, tends
to become resistant to hormone therapy within 1 -2 years and the treatment usually does
not result in cure.

Chemotherapy
This treatment involves use of drugs such as docetaxel that primarily function to
destroy fast growing cells that are often present in tumors. Chemotherapy is mostly used
in combination with other treatments when hormone therapy fails and/or when disease is
advanced. However, it is also often used as the only treatment in patients with high-risk
PCa, advanced disease and metastases. Chemotherapy can have numerous side effects
(nausea, vomiting, hair loss, anorexia, diarrhea, infertility, increased susceptibility to
infections due to decline in leukocyte counts, etc.) and resistance can emerge.

Prostatectomy
It is most often used in early stages of PCa, when the tumors are still localized to
the area of the prostate and thus accessible by surgery. Treatment involves surgical
removal of the prostate gland. Variations in this procedure include radical prostatectomy,
transurethral resection of the prostate and cryosurgery. Urinary incontinence and
impotence are among the most common side effects.

Radiation Therapy
In the treatment of PCa, radiation therapy is most commonly used in cases where
the tumor is still localized within the prostate gland or nearby tissue, i.e. stages 1 and 2
5

(Nilsson, et al., 2004). In this treatment, ionizing radiation is utilized as a tool for cancer
destruction. Treatment efficacy is maximized at higher doses, but limited due to normal
tissue toxicity. As exposure to radiation inevitably leads to normal tissue damage, an
optimal radiation dose requires that maximum tumor destruction be achieved with
minimal damage to normal tissues. Higher dose of radiation cause a variety of side
effects, ranging from short term, acute to long term and chronic. The nature and length of
the side effects depend on the radio sensitivity of the tissue, radiation dose and overall
health of the patient. Improvements have been made in the field of radiotherapy and thus
have paved way for dose escalation; studies have shown that higher doses (up to 78Gy)
are necessary to achieve optimal tumor control. However, it has been established that
there is increased risk for urinary and rectal toxicities with the use of higher radiation
doses. Patients have been shown to have an increased rate of severe complication when
more than >25% of the rectum was irradiated at doses >70Gy (Zelefsky, et al., 2006a).
Complications include chronic proctitis, rectal bleeding, increased urinary frequency,
urethral stricture, impotence and gastrointestinal problems. In addition, higher dose levels
have the potential for increasing the risk for long-term morbidity.
Radiation-induced damage occurs as a result of energetic particles or
electromagnetic waves (photons) interacting with the cells and transferring their energy
to different molecules within or on the cell. The amount of energy must be sufficient to
ionize an atom; examples are X-rays and gamma-rays. Interactions of ionizing radiation
with cellular components lead to tissue damage that can be induced by either direct or
indirect pathways. By way of the direct pathway, charged particles/photons directly
interact with target cellular structures such as the DNA causing ionization and excitation
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leading to damage. Ionization of DNA by radiation results in Multiply-Damaged-Sites
(MDS) which consist of multiple clustered base lesions such as cross-linking, oxidized
bases and single- and double-strand breaks (Eot-Houllier, Eon-Marchais, Gasparutto, &
Sage, 2005; Zelefsky, et ah, 2006a). In the indirect pathway, the particles produce free
radicals by ionizing water and other molecules, which in turn interact with other
molecules and cellular components. The energetic particles are highly unselective and
can cause tissue damage by ionizing any molecule, but ionization of water and the DNA
are of major consequence. This is due to the facts that: a) the cell consists of 80% water
that absorbs most of the energy, leading to rapid production of highly reactive free
radicals that can interact with other cellular components and b) the DNA is essential in
nucleated cells and oxidation of bases can lead to mutations and irreparable damage.

Reactive Oxygen Species (ROS)
ROS and other free radicals are often defined as molecules containing one or more
unpaired electrons, which confer them with a considerable degree of reactivity. They are
usually derived from oxygen and are produced by all aerobic organisms as a product of
metabolism and in response to extracellular stimuli (Valko, et ah, 2007; Zelefsky, et al.,
2006a). They include superoxide, (CV) hydrogen peroxide, (H2O2) hydroxyl radical
(OH‘), peroxynitrite, (ONOCT). They are produced from both endogenous and exogenous
sources such as inflammatory cell activation, radiation, metal-catalyzed reactions and in
the mitochondria as by-products of electron transport chain reactions (Valko, Rhodes,
Moncol, Izakovic, & Mazur, 2006). These ROS are known to react with various
components of the cell, often resulting in DNA oxidation, lipid peroxidation and protein
damage (Figure 1).
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Although ROS have predominantly been viewed as damaging in regard to the
cellular environment, it should be noted they also play a major role in normal
physiological activity; however, the effects vary depending on the concentration and
length of exposure. Typically low ROS concentrations are required to sustain normal cell
physiology; and are involved in cellular metabolism and signaling pathways such
mitogen-activated protein kinases (MAPK), phosphoinositide 3 (PI-3)/AKT protein
kinases, phospholipase C-yl (PLC-yl), protein kinase C (PKC), p53, activator protein 1
(AP-1), hypoxia-inducible factor-la (HIF-la) and nuclear factor-xB (NF-kB) (Droge,
2002; Genestra, 2007; Lopez-Lazaro, 2007; Martindale & Holbrook, 2002). These
pathways are involved in regulation of cellular processes ranging from cell survival and
proliferation to senescence and death (Droge, 2002; Trachootham, Lu, Ogasawara, Nilsa,
& Huang, 2008). A balance in cellular ROS concentrations is very important in
maintaining a normal physiological redox state. ROS can either be beneficial or harmful
depending on the environment and type of cell. Some of the beneficial effects include
response to infections agents, maintenance of vascular tone and induction of myogenic
tone (Terashvili, Pratt, Gebremedhin, Narayanan, & Harder, 2006; Touyz & Schiffrin,
2004). In contrast, high ROS concentrations lead to oxidative stress and cause damage to
the DNA, proteins and lipids (Figure 1).
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Diseases and ROS
Unregulated and/or prolonged exposure to elevated ROS concentrations has been
linked to cancer development and progression (Figure 2). This increase alters the redox
status of the cell and activates gene expression and signaling pathways associated with
neoplastic transformation (Fu, et ah, 2007; Peled, Zipori, & Rotter, 1996; Pikarsky &
Ben-Neriah, 2006), thus leading to altered cell cycle progression, increased cellular
proliferation, survival and evasion of apoptosis (Bonello, et ah, 2007). Nonetheless, ROS
concentrations can be high enough to be toxic even to malignant cells, as seen in cancer
treatment with chemotherapy and radiotherapy. Oxidative stress has been widely
implicated in a variety of diseases, such as cancer, aging, arteriosclerosis, arthritis,
neurodegenerative disorders, diabetes, cardiovascular diseases and ischemia-reperfiision
injury (Droge, 2002; Martindale & Holbrook, 2002; Valko, et ah, 2007).
Elevated ROS concentrations have been implicated in carcinogenesis, cancer
progression and metastasis (Wu, 2006). Cancer development is a multistage process that
is characterized by accumulation of multiple events including DNA damage, inhibition of
antioxidant defense and cell death pathways, induction of cell survival and proliferation,
amplification of pro-angiogenic pathways and acquisition of self sufficiency in growth
signals (Hanahan & Weinberg, 2000). All of these changes accumulate as tumors develop
and progress, leading cells towards genetic damage and further genomic instability. The
involvement of ROS in cell signaling and consequently gene expression has been clearly
established in cancers and other diseases (Klaunig & Kamendulis, 2004; Wu, 2006); thus,
the importance of maintaining ROS levels within a range that is beneficial cannot be
overstated.
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Antioxidants
Antioxidant activity is central to regulation of reduction-oxidation reactions and
maintaining a balance in ROS concentrations (Figure 3). Antioxidants are responsible for
the direct removal of ROS and other free radicals from the cellular environment.
Endogenous defenses against ROS consist of both enzymatic and non-enzymatic
antioxidants. Vitamin C, vitamin E, carotenoids, glutathione, thioredoxin and flavanoids
are examples of non-enzymatic antioxidants. Enzymatic antioxidants, which account for
the majority of the cellular antioxidant activity, include superoxide dismutase (SOD),
catalase and glutathione peroxidase (Klaunig & Kamendulis, 2004; Valko, et al., 2006).

Superoxide Dismutase (Sod) Mimetics
SOD is responsible for the dismutation of superoxide to O2 and H2O2. Naturally
occurring SODs have an active metal center involved in its catalytic activity. In humans,
there are 3 forms of this antioxidant: Cu/Zn-SOD found in the cytosol and extracellularly
and Mn-SOD in the mitochondria. The metalloproteins have been used to attenuate ROSinduced injury in a variety of disease models including cancer (Salvemini, Riley, &
Cuzzocrea, 2002). However, the use of naturally occurring and genetically engineered
SODs in the clinical setting has unfortunately been limited due to short half-lives, poor
cell delivery, antigenicity/hypersensitivity and high cost of production (Salvemini, et al.,
2002). As a result, SOD mimetics have been designed to overcome these limitations.
They have a low molecular mass and a redox-active metal center which functions
similarly to naturally occurring SODs in scavenging for ROS. Small molecular weight
metalloporphyrins are broad spectrum antioxidants; in addition to their function as SOD
12

mimetics, they scavenge other free radicals such as lipid peroxides and reactive nitrogen
species (RNS), i.e. nitric oxide (NO), peroxynitrite (ONOO') and the carbonate radical
(CO3') (Ferrer-Sueta, Quijano, Alvarez, & Radi, 2002; Ferrer-Sueta, et ah, 2003;
Spasojevic, Batinic-Haberle, & Fridovich, 2000). They are stable non-peptide molecules
and thus can avoid the allergic reactions associated with bovine or recombinant SOD;
furthermore they have a longer half life, better cell permeability, more potent antioxidant
activity and are less expensive (Day, 2004; Klaunig & Kamendulis, 2004; Patel & Day,
1999).
Manganese (III) meso-tetrakis (1, 3-diethylimidazolium-2-yl) porphyrin is a
metalloporphyrin SOD mimetic (AEOL10150), consisting of a porphyrin ring with a Mn
center and ethylimidazolium side chains (Figure 4). Recent studies have demonstrated the
ability of AEOL10150 to protect normal tissues against radiation-induced damage
(Bowler, et al., 2002; Orrellj 2006; Rabbani, Batinic-Haberle, et ah, 2007; Rabbani,
Salahuddin, et al., 2007).
Our previously published studies further suggest that AEOL10150 does not
protect tumors against radiation damage and may have modest anti-tumor effects
(Gridley, et al., 2007). As emerging research demonstrates possible anti-tumor properties
of SOD mimetics in addition to normal tissue protection, understanding their mechanisms
of action becomes more significant as they may have the potential to enhance radiation
therapy for cancer.
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MnTE-2-PyP
MnTE-2-PyP (Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin) is an SOD
mimetic that contains a Mn2+ at the center of a porphyrin ring (Figure 5). Although it is
somewhat comparable to AEOL10150, it has ethylpyridinium side chains in place of the
ethylimidazolium side chains (Figures 4 and 5). These modifications on the
metalloporphyrin backbone confer markedly different antioxidant activity/properties on
these two compounds (Table 1) The alternate oxidation-reduction reaction of the Mn
moiety in MnTE-2-PyP is responsible for the dismutation of superoxide. It has also been
reported to have catalase activity; although the level of this activity is less than 1% of
native catalase, it is still able to protect cells from F^CTrmediated toxicity (Mackensen, et
ah, 2001).
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Figure 5. Structure of MnTE-2-PyP. A porphyrin complex with a Mn+ center and four
positively charged ethylpyridinium side groups (Mackensen, et ah, 2001).
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Table 1. Comparison of antioxidant activity of SOD mimetics.ICSO: 50% inhibition
concentration(Mackensen, et al., 2001) .

Antioxidants

SOD Activity
(U/mg)

Catalase
(min-l)

CuZnSOD

5,100

AEOL10150
(MnTDE-2-ImP)

5,000

1

MnTE-2-PyP

8,500

1.41

Lipid Peroxidation
(IC50, pM)
15
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The Immune System
The immune system is composed of a complex network of organs and specialized
cells that defend the body from invading infectious agents (bacteria, viruses, fungi, etc.)
and other foreign “invaders.” It has the ability to distinguish self from non-self (foreign
or abnormal) cells by identifying markers on the cell surface; the major
histocompatibility complex (MHC) often plays an important role in this process. MHC
class I and II molecules, together with a number of accessory proteins are responsible for
presenting peptides derived from antigens to T cells and are crucial to activation of an
adaptive immune response. The adaptive or cell-mediated component of the immune
system is regulated by the T lymphocytes (Kindt, Goldsby, Osborne, & Kuby, 2007). T
cells consist of two main sub-populations, T helper (CD4+ or Th) and cytotoxic T (CD8+
or TC) that act differently in response to foreign antigens. Th cells coordinate immune
responses by secreting cytokines which function to stimulate production of antibodies by
B cells, recruit phagocytes and further modulate T cell activation (i.e., by either up- or
down-regulation). In contrast, Tc cells directly destroy foreign cells once they have been
primed by antigen-presenting cells. B lymphocytes are also part of adaptive immunity.
However, in contrast to T cells, they can recognize antigen in its native form while it is
soluble in the blood or lymph using their membrane bound-immunoglobulin as the
receptor. When activated, B cells secrete antibodies that consist of five major isotypes
(Kindt, et al., 2007). The antibodies, in turn, bind to antigens (soluble or on cell surface)
so that their removal/destruction is facilitated.
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Additional immune cells include monocytes, macrophages, natural killer cells
(NK), dendritic cells (DC) and granulocytes (Figure 6); these cells are part of the innate
or natural component of the immune system. DC cells and cells of the monocytemacrophage lineage can act as antigen-presenting cells. In addition, the monocytemacrophages, as well as neutrophils (the most abundant type of granulocyte), are highly
efficient at phagocytosis, resulting in ROS that contribute greatly to destruction of
whatever was ingested. In cases of chronic inflammation, these cells contribute
significantly to tissue injury due to excessive and prolonged release of ROS and other
unstable radicals. The NK cells are similar in function to Tc cells in that they can directly
kill target cells, but they do not require antigen presentation via the MHC class I/II and
thus have the potential to recognize a broader range of foreign cells (Kindt, et ah, 2007).
All cells of the immune system are originally derived from the bone marrow via
hematopoiesis. Bone marrow-derived stem cells differentiate into mature cells that
circulate in the blood and lymphatic systems or into precursors that mature as they
migrate to other organs including the thymus, lymph nodes, spleen, and liver. B, NK
cells, DC and granulocytes mature in the bone marrow while thymocytes migrate to the
thymus where they mature into T lymphocytes. Monocytes in peripheral blood
differentiate into macrophages when they migrate into tissues. The spleen serves as a
central site for mounting an immune response; it has numerous areas of white pulp that
has a high content of T and B lymphocytes and a reticuloendothelial system with
monocyte-macrophages. Removal of the spleen or destruction of its cellular components
by radiation increases the possibility for infection and other pathologies.
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Cytokines are regulatory proteins secreted by cells of the immune system, as well
as many other cell types. Their pleiotropic actions include mediating and regulating
immunity, inflammatory responses that include ROS production, hematopoiesis, cell
proliferation, tissue repair, angiogenesis and a host of additional biological processes.
Cytokine interactions are complex and cellular responses are highly dependent on the
type of cell and the receptors present on their membranes. Their roles in the immune
system are critical to the development and functioning of both the innate and adaptive
immune responses (Feldmann, 2008; Oppenheim, 2001; Scheinecker, Redlich, &
Smolen, 2008; Vilcek & Feldmann, 2004).
The Immune System: Its Role In Cancer Response And Radiotherapy
Tumors result from a dynamic shift in the delicate balance of intrinsic pathways
involving oncogenes and tumor suppressors following external stimuli (such as
carcinogenic agents) or the dysregulation of extracellular pathways (such as chronic
inflammation). Tumor presence promotes activation of pathways that would enhance
survival and proliferation of neoplastic cells while inhibiting those that make them more
susceptible to cell death, controlled proliferation and immune recognition.
Immune surveillance with subsequent destruction of aberrant cells is a welldocumented phenomenon. When the immune system is depressed or dysfunctional, e.g.,
in organ transplant recipients and patients with human immunodeficiency type-1 (HIV-1)
infection, cancer prevalence is markedly increased (Vajdic & van Leeuwen, 2009). As for
many other types of cancers, much research has been devoted to evaluating
immunotherapeutic approaches for PCa, including cytokine-based therapies and vaccines
(Harzstark & Small, 2009). In a very recent phase III clinical trial involving men with
metastatic, androgen-independent PCa, a vaccine (Provenge) reportedly prolonged
22

survival time (http://www.webmd.com/prostate-cancer/news/20090414/prostate-cancervaccine-provenge-meets-goal). It remains to be determined whether the vaccine will gain
approval from the Food and Drug Administration (FDA). Overall, a major challenge for
the immune system is distinguishing antigens on malignant cells from those on normal
self cells (Seliger, 2005). In addition, the diminished capacity of immune recognition of
tumors is believed to be the result of down-regulated tumor-associated antigens, secretion
of immunosuppressive cytokines, impairment of antigen presentation and loss of MHC
class I expression (Croci, et al., 2007; Khong & Restifo, 2002; Seliger, 2005).
Cytokines play a major part in immune activation and regulation during immune
surveillance against neoplastic cells. They are implicated in a variety of pathways that
have been “hijacked” to the advantage of tumors. Such pathways include anti
inflammatory responses that involve signal transducer and activator of transcription-3
(STAT3) and Janus kinase (JAK)-STAT. Immunosuppressive pathways involve
transforming growth factor-p (TGF-p) and interleukin-10 (IL-10), while pro-angiogenic
pathways include VEGF (Mocellin & Nitti, 2008). Activation of these latter pathways
can facilitate tumor development and progression.
Radiotherapy has historically been viewed as immunosuppressive (Wasserman, et
al., 1982; Wasserman, Blomgren, Rotstein, Petrini, & Hammarstrom, 1989) and often
associated with lymphocyte radiosensitivity (Chambers, Harrington, Ross, & Filion,
1998; Harrington, Chambers, Ross, & Filion, 1997; Kajioka, et al., 1999). However,
recent studies suggest a more varied effect of radiotherapy on the immune system
(Gridley & Slater, 2004), especially in application to cancer treatment (Demaria &
Formenti, 2007). It is now becoming clear, as seen with the administration of therapeutic
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cancer vaccines, that dead or dying cancer cells are significant to the immune response of
the host (Demaria & Formenti, 2007). Dead or dying cells serve as a good source of
antigens (in this case tumor-associated antigens) that have the potential to produce
“danger signals” that induce DC maturation and presentation of antigen to T cells,
promote B cell production of anti-tumor antibody and enhance innate immune
mechanisms (Demaria & Formenti, 2007; Roses, Xu, Koski, & Czemiecki, 2008).

Nuclear Transcription Factors
Nuclear Factor-icB (NF-kB)
NF-kB is a transcription factor that plays important roles in regulation of
inflammation, apoptosis, stress response, cellular proliferation, differentiation and
migration (Karin, Cao, Greten, & Li, 2002; Sarkar & Li, 2008). The NF-kB family is
made up of two classes of five proteins. The first class is Rel A (p65), Rel B, c-Rel; these
proteins are synthesized in their mature form and have transcription-modulating domains
at their C-terminus. The NF-kB 1 (pi05) and NF-kB2 (pi00) factors that belong to the
second class, on the other hand, are synthesized as large precursors that are processed
into their mature forms p52 and p50, respectively. These latter two proteins form dimers
and are present in the cytoplasm in an inactive form. The dimers are sequestered by
inhibitors of kB (IkB) such as IkBoc and IkB(3; pi05 and pi00 also function as IkB
proteins due to the presence of multiple ankyrin repeats. Unlike IkB proteins, pi 00 and
pi 05 are present on their C-terminus. Degradation of IkBs occurs as a result of signalinduced IkB kinase (IKK) activation and consequently activation of NF-kB. In response
to signal activation, IKK phosphorylates the IkB in its regulatory domain resulting in
ubiquitination and degradation by the proteasome. Upon degradation of IkB, the NF-kB
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is free to enter the nucleus where it activates genes responsible for the observed
physiological responses. Activation of NF-kB is triggered by a variety of stimuli such as
cytokines, ROS, ionizing radiation and pathogens (Figure 7) (Bonello, et ah, 2007;
Criswell, Leskov, Miyamoto, Luo, & Boothman, 2003; Genestra, 2007; Gorlach &
Bonello, 2008; Pikarsky & Ben-Neriah, 2006).
NF-kB activation has also been implicated in carcinogenesis, cancer progression
and resistance to chemotherapy (Sweeney, et al., 2004). It is constitutively activated in
various cancers and promotes cellular proliferation, inhibition of apoptosis, metastasis
and angiogenesis (Figure 8) (Karin, et al., 2002; Kim, Hawke, & Baldwin, 2006;
Nakshatri, Bhat-Nakshatri, Martin, Goulet, & Sledge, 1997; Sweeney, et al., 2004).
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Hypoxia Inducible Factor la (Hif-la)
HIF-1 a is a transcription factor responsible for the regulation of a variety of genes
involved in numerous processes such as erythropoiesis, energy metabolism, cell survival,
apoptosis, cell adhesion, angiogenesis and motility. It is a heterodimeric complex
composed of a constitutively expressed (3 subunit and a hypoxia regulated a subunit. The
HIF-1 a consists of two trans-activating domains responsible for its regulation as a
function of O2 concentration; under normal conditions these domains are modified and
tagged for degradation by ubiquitination. It is generally accepted that HIF-1 a dimerizes
and is activated under hypoxic conditions, however, recent reports suggest that it can also
be up-regulated under normoxic conditions in response ROS (Figure 9) (Bonello, et al.,
2007). Under conditions of inadequate oxygen supply (or hypoxia), HIF-1 a degradation
is diminished leading to rapid accumulation and translocation into the nucleus where it
forms a dimer with HIF-1 (3. The activated HIF-1 protein initiates transcription from target
genes by binding to the hypoxia response element (HRE), located in their promoter or
enhancer regions.
HIF-1 a allows tumor cells to adapt to their microenvironment by stimulating the
expression of a large number of hypoxia-related genes. As tumor masses enlarge, they
become hypoxic resulting from the increased pressure on existing vasculature, thus
reducing oxygen supply and nutrients. The areas furthest away from the blood vessels
(usually sites within the tumor mass, rather than at the periphery) are most affected
resulting from the disparate vascular distribution. HIF-1 a enhances the malignant
phenotype, as well as tumor growth, by altering gene expression and the tumor's
metabolic microenvironment and by inducing the formation of new blood vessels. It has
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been associated with resistance to anticancer radiotherapy and chemotherapy, increased
metastasis and poor survival in patients (Moeller & Dewhirst, 2006).

Role of NF-icb and HIF-ot in Carcinogenesis and Cancer Progression
ROS are among a very extensive list of factors that have been implicated in
carcinogenesis, tumor survival and progression and no one single mechanism can fully
explain it. Current literature shows that ROS play an important role in HIF-lcc and NFkB

activation (Figures 7 and 9) (BelAiba, et ah, 2004; Bonello, et ah, 2007; Gorlach &

Bonello, 2008). Increased ROS concentration has been implicated in activation and
elevated expression of NF-kB and HIF-lcc, events which are associated with poor
prognosis, radiation resistance in solid tumors, cancer progression, metastasis,
angiogenesis and proliferation (Galanis, et ah, 2008). Several studies have demonstrated
the role of NF-kB in HIF-la activation in response to ROS (Bonello, et ah, 2007;
Gorlach & Bonello, 2008; van Uden, Kenneth, & Rocha, 2008). van Uden and colleagues
have demonstrated the presence of a functional NF-kB binding site on the HIF-la
promoter (van Uden, et ah, 2008).
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Purpose of This Study
Combination treatment in prostate cancer therapy is currently a fast emerging
trend in attempts to increase the rate of cure by maximizing tumor destruction with
minimal damage to normal tissue. A major limitation in successful radiation therapy is
the increase in normal tissue damage as higher doses are used to achieve greater tumor
destruction. Antioxidants have been shown to protect normal tissues against radiation
damage; however, it is essential that they do not protect the tumor. MnTE-2-PyP is a well
established and effective free radical scavenger in stroke (Shimizu, Rajapakse, Horiguchi,
Payne, & Busija, 2003), diabetes (Haskins, et al., 2003), sickle cell anemia (Kaul, et al.,
2006), Alzheimer’s disease models (Sompol, et al., 2008), asthma and chronic
inflammation (Rahman, 2008); radioprotective effects have also been demonstrated in
irradiated lungs (Chang, et al., 2003; Vujaskovic, et al., 2002).
Radiation up-regulates HIF-la expression (Moeller, Cao, Li, & Dewhirst, 2004)
and contributes to resistance of tumor to radiotherapy (Moeller & Dewhirst, 2006). Our
previously published data shows that in combination with AEOL10150, an SOD mimetic
similar to MnTE-2-PyP, radiation-induced HIF-la up-regulation is significantly
decreased (Gridley, et al., 2007). Essential to our proposal here was the role of ROS in
cancer progression and immune modulation, as they relate to nuclear transcription factors
NF-KBand HIF-la.
ROS have the ability to modify various signaling pathways, including NF-kB and
HIF-la activation. These pathways are involved in growth regulation and cell
survival/death and have been implicated in carcinogenesis, cancer progression, metastasis
and resistance to certain treatments (Karin, et al., 2002; Kim, et al., 2006; Klaunig &
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Kamendulis, 2004; Nakshatri, et al., 1997; Sweeney, et al., 2004). Although exact
mechanisms by which the cellular redox state modifies cell activity are not yet fully
elucidated, their involvement is evident. Molecular events such as evasion of apoptosis,
increased cellular proliferation and senescence have been identified as hallmarks of
cancer (Hanahan & Weinberg, 2000) and have been associated with pro-oxidative redox
states (Klaunig & Kamendulis, 2004; Valko, et al., 2007; Valko, et al., 2006).
Metalloporphyrin antioxidants, such as MnTE-2-PyP, scavenge for ROS and have
the capacity to alter cellular signaling (Salvemini, et al., 2002). Our main goal was to
determine the effect of MnTE-2-PyP on PCa response to radiation and investigate
possible mechanisms responsible for the observed effects. In order to be clinically
relevant, the drug must not protect tumor against radiation damage. The use of
antioxidants in combination with radiation raises controversy (Block, 2004; Ladas, et al.,
2004; Moss, 2007; Prasad & Cole, 2006) and concern among clinicians because it is well
known that about two-thirds of radiation-induced damage is through generation of ROS
(Roots & Okada, 1975). Thus, the use of antioxidants that scavenge ROS has the
possibility of diminishing the therapeutic efficacy of radiation. In addition, since
radiation is well established to be immunodulatory, we wanted to investigate the effect of
MnTE-2-PyP, alone and in combination with radiation, on bone marrow-derived cell
populations.
Our major goal was to gain a better understanding of the mechanisms by which
MnTE-2-PyP may affect tumor growth when used alone and in combination with
radiation. Data generated previously in our laboratory with metalloporphyrin
antioxidants, as well as observations by other investigators, led to the following
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hypotheses: 1. MnTE-2-PvP will not decrease the efficacy of radiation against
tumors growing in vivo. 2. Administration of MnTE-2-PvP will modify distribution
of immune cell populations and levels of cytokines that affect immune function and
tumor angiogenesis. 3. MnTE-2-PvP will have a direct effect on tumor cells by
altering proteins that are important in hypoxia-inducible signal transduction
pathways. These hypotheses were addressed in the aims listed below.
Specific Aim 1. Determine if MnTE-2-PyP, both with and without radiation, alters
prostate tumor growth, immune cell distribution and levels of circulating and secreted
cytokines that affect tumor angiogenesis and immune responsiveness using the RM-9
mouse model that simulates PCa in humans.
Specific Aim 2. Determine if MnTE-2-PyP modulates radiation-induced changes
in DNA synthesis and the apoptotic response in prostate cancer cells in vitro and
determine if differences exist between the mouse RM-9 and human prostate cancer cell
lines.
Specific Aim 3. Investigate and compare the effects of MnTE-2-PyP on NF-kB
and HIF-la signaling using the mouse RM-9 tumor and prostate cancer cell lines.
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CHAPTER TWO
EFFECT OF A METALLOPORPHYRIN ANTIOXIDANT (MnTE-2-PYP) ON THE
RESPONSE OF A MOUSE PROSTATE CANCER MODEL TO RADIATION
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Abstract
Background: Metalloporphyrin antioxidants can protect tissues against radiationinduced damage. However, for effective use in radiotherapy as normal tissue
radioprotectants, they must not protect the cancer. The major objectives were to evaluate
the effects of Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin (MnTE-2-PyP) on
tumor response to radiation and explore mechanisms responsible for the observed effects.
Materials and Methods: C57BL/6 mice were subcutaneously (s.c.) injected with RM-9
prostate tumor cells on day 0 and grouped according to treatment with MnTE-2-PyP (s.c.
6 mg/kg/day beginning on day 1 for 16 maximum days), 10 gray (Gy) single fraction
radiation on day 7, or combination of both. Subsets per group and non-tumor bearing
controls were evaluated for leukocyte populations, red blood cell (RBC) and platelet
characteristics, and cytokines on day 12; remaining mice were followed for tumor
growth. Results: Although radiation alone significantly slowed tumor growth and
addition of MnTE-2-PyP resulted in slightly slower tumor progression, the difference
between radiation and radiation plus drug was not statistically significant. However,
treatment with drug alone significantly elevated T (Th, Tc) and natural killer (NK) cells
in the spleen, B cells in blood and spleen, and the capacity to produce interleukin-2.
Addition of the drug to radiation did not ameliorate the depression seen in all major
leukocyte types, but did protect against radiation-induced decreases in RBC counts,
hemoglobin, and hematocrit. Vascular endothelial growth factor was increased in plasma
from both irradiated groups and a trend for increased transforming growth factor-(31 was
noted with radiation alone. Conclusion: MnTE-2-PyP did not protect RM-9 prostate
tumor against radiation damage and was not toxic under the conditions used. The drug36

induced enhancement of certain immune parameters suggests that MnTE-2-PyP may be
beneficial not only as a normal tissue radioprotectant, but also as a facilitator of anti
tumor immunity.

Introduction
Radiation therapy is a highly relevant modality in the treatment of prostate cancer.
However, sensitivity of the surrounding tissue to radiation inevitably leads to normal
tissue damage with varying degrees of severity. An optimal radiation dose requires
maximum tumor destruction with minimal damage to normal tissues. Higher doses of
radiation have been reported to cause a variety of side effects, ranging from short-term
acute to long-term and chronic (Storey, et al., 2000). The nature and duration of the side
effects depend on the radio sensitivity of the tissue, total radiation dose, fractionation
scheme, and overall health of the patient.
Radiation induces tissue toxicity directly by damaging DNA and indirectly via the
production of reactive oxygen species (ROS). As radiation causes elevation in ROS
levels, the ROS are bound to interact with cellular components vital to various signaling
cascades, apoptosis/cell cycle regulation, and vascular proliferation/angiogenesis. In this
context, the fate of the cells ultimately depends on the interaction of ROS with these
cellular processes. Cytokines secreted by leukocytes are among the many molecules
expressed in response to ROS. Since they play important roles in cellular signaling, the
pattern of cytokine expression due to elevated ROS could be especially crucial in the
response of cells to radiation (Aebersold, et al.). Tumor growth modulation by cytokines
can have both direct and indirect effects on angiogenesis, as well as on host anti-tumor
immunity mediated by T lymphocytes and natural killer (NK) cells. Transforming
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growth factor-beta 1 (TGF-(31) and vascular endothelial growth factor (VEGF) are two
major cytokines that respond to oxidative stress and regulate angiogenesis (Abate-Shen &
Shen, 2000; Barcellos-Hoff & Dix, 1996; Jobling, et ah, 2006; Koli, Myllamiemi, KeskiOja, & Kinnula, 2008; Li, Guo, Bemabeu, & Kumar, 2001). In contrast, the ability to
produce interleukin-2 (IL-2), a T helper (Th) cell-derived cytokine important in
facilitating immune attack against tumors, can be compromised by exposure to radiation
(Kusunoki & Hayashi, 2008).
TGF-pl is an effective and ubiquitous modulator of cell growth and its biphasic
role in carcinogenesis is significant. In early stage carcinogenesis, it acts as a tumor
suppressor, inhibiting cell growth; in later stages, it functions as a tumor promoter,
enhancing cell growth, invasion, and metastasis, in part by decreasing host-tumor
immune response (Abate-Shen & Shen, 2000; Bierie & Moses, 2006; Rich, Borton, &
Wang, 2001). TGF-(31 has been shown to be a key modulator of angiogenesis by
regulating endothelial cell proliferation, migration, extracellular matrix (ECM)
metabolism, and the expression of adhesion molecules (Abate-Shen & Shen; Li, et ah,
2001). It is important to also note that TGF-pl is a highly immunosuppressive cytokine
that is secreted by the Th3 subset, as well as by many malignant cell types (Teicher,
2007).

VEGF plays a central role in both normal and tumor angiogenesis (Walsh, 2007).
It enhances proliferation, migration, and invasion of endothelial cells into tumors
resulting in new blood vessel formation, and thus also increases risk for tumor
progression. Low oxygen tension causes up-regulation of VEGF. As tumors develop and
become more malignant, they become more hypoxic because of the inability of the
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existing vasculature to supply sufficient oxygen to all parts of the tumor mass; radiation
compounds these hypoxic conditions by damaging already established vessels and
causing elevated ROS levels. These conditions lead to altered gene expression in favor
of increased cell survival, angiogenesis, and metastasis (Vaupel & Mayer, 2005).
Elevated levels of VEGF have been associated with increased tumor metastasis and poor
prognosis for patients with cancer of the prostate (Duque, et al., 2006; Green, et al.,
2007), as well as other body sites.
IL-2 is a major cytokine secreted by activated Thl lymphocytes. The factor has
long been known to be essential for T cell growth and differentiation. IL-2 acts as a
signaling molecule by binding to an IL-2 receptor complex on the surface of
lymphocytes, thereby inducing effector cell functions that include destruction of tumor
cells. The administration of IL-2 has resulted in eradication of advanced cancers in some
patients, but serious toxicities and unpredictability in therapeutic effectiveness have
limited its usefulness (Jin, Wang, Provenzano, Stroncek, & Marincola, 2007). Recent
studies have demonstrated that IL-2 is indispensable not only for T cell activation, but
also for the maintenance of tolerance to self antigens (Bachmann & Oxenius, 2007).
Antioxidants are responsible for detoxifying ROS and are the central cellular
defense mechanism against oxidative damage. The groups of antioxidants include
superoxide dismutases (SODs), catalase (CAT), and glutathione (GPx). SODs play a
critical role in the eradication of ROS; they are responsible for the dismutation of
superoxide, O2 ‘, to H2O2, which can then be reduced to H2O and O2 by CAT. It has been
shown that elevated levels of SODs have a protective effect against oxidative stress
(Salvemini, et al., 2002). The clinical use of endogenous SODs has unfortunately been
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limited due to their short circulating half-lives, hypersensitivity induction, large
molecular weight (Mr ~30kDa), poor cell delivery, and cost of production. As a result,
SOD mimetics have been developed in efforts to overcome these limitations. The basic
required properties are stability and non-toxicity; in addition, they should have low
molecular mass, and most importantly scavenge effectively for ROS (Salvemini, et al.,
2002; Vujaskovic, et al., 2002).
Small molecular weight metalloporphyrin SODs can function as SOD mimetics.
In addition to scavenging O2 ', they also scavenge H2O2, lipid peroxyl radicals, and
reactive nitrogen species (RNS), i.e. nitric oxide (NO), peroxynitrite (ONOO ), and the
carbonate radical (CO3') (Ferrer-Sueta, et al., 2003; Spasojevic, et al., 2000). It has been
reported that SOD mimetics are effective free radical scavengers in models of stroke
(Shimizu, et al., 2003), diabetes (Haskins, et al., 2003) ,and sickle cell anemia (Kaul, et
al., 2006). They have been shown to protect normal tissues against radiation-induced
damage presumably by preventing or at least minimizing oxidative stress (Vujaskovic, et
al., 2002). In addition, there is mounting evidence that SOD mimetics may enhance
tumor radioresponsiveness (Moeller, et al., 2005a). Our previous studies with the RM-9
mouse prostate model have also shown that the use of SOD mimetics may facilitate the
anti-tumor effect of radiation (Gridley, et al., 2007).
MnTE-2-PyP (Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin) has been
shown to protect normal tissues from radiation-induced injury (Vujaskovic, et al., 2002)
and has been highly effective in a wide variety of other models of oxidative injury
(Chang, et al., 2003; Lubbers, Polakowski, Crapo, Wegner, & Cox, 2003; Mackensen, et
al., 2001; Vujaskovic, et al., 2002). This compound contains a Mn2+ at the center of a
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porphyrin ring with ethylpyridinium side chains (Figure 5). Alternate oxidation-reduction
reaction of the Mn moiety is responsible for the dismutation of O2 ' into oxygen and
hydrogen peroxide. This mechanism of O2 scavenging is similar to the naturally occurring
SOD.
In our previous studies with MnTDE-2-ImP (Figure 4), an SOD mimetic
structurally similar to MnTE-2-PyP, administration to RM-9 prostate tumor-bearing mice
that also received radiation treatment significantly slowed tumor growth and decreased
the expression of hypoxia-inducible factor-la (HIF-la) in comparison to animals that
received radiation alone (Gridley, et al., 2007). HIF-la an oxygen-regulated transcription
factor, is known to regulate the genes for the hypoxia responsive element (HRE),
including those for VEGF and TGF-(31. Examining VEGF and TGF-pl levels might give
insight into mechanisms responsible for the activity of SOD mimetics in combination
with radiation. Thus, the major objectives of this study were to determine if MnTE-2PyP can be used in combination with radiation in the RM-9 mouse prostate tumor model
and to further investigate possible mechanisms of interaction. The emphasis was on
leukocyte populations that respond to tissue damage, secrete cytokines, and have anti
tumor properties.

Materials and Methods
Animals
Eight to 9 week old male C57BL/6 mice (n = 87) were purchased from Charles
River Breeding Laboratories Inc. (Hollister, CA, USA) and acclimatized for about 1
week prior to initiation of study. They were housed under standard temperature,
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humidity, and 12-h light/dark cycling conditions. Food and water were provided ad
libitum. The mice were weighed and observed routinely for signs of toxicity. Rapid CO2
euthanasia was performed under the approved Institutional Animal Care and Use
Committee (IACUC) protocol and in compliance with the National Institutes of Health
(NIH) Guide for the Care and Use of Laboratory Animals.

Treatment Groups
Animals were randomly assigned to 5 groups based on treatment received. Four
groups were tumor-bearing and assigned as follows: i) No treatment, ii) Drug, iii)
Radiation, and iv) Drug + Radiation. A fifth group with no tumor was designated to serve
as the baseline control for in vitro assays that were also performed on a subset from each
of the tumor-bearing groups. Mice used for in vitro analyses, both with and without
tumor (n = 8-10/group), were euthanized 12 days after tumor cell implantation; all
remaining animals had tumor (n = 10-12/group) and were euthanized individually when
tumor volume reached the maximum allowed (~2,000 mm3) or at termination of the study
on day 21.

Tumor Cell Line
RM-9 is a prostate cancer cell line that was originally derived from a ras + myc
transformed/wild-type TP53 primary prostate tumor induced in the Zipras/myc-9-infected
mouse prostate reconstitution (MPR) model using C57BL/6 mice. This cell line has been
extensively evaluated for pathological and phenotypic characteristics and was selected
because of its close similarity to human prostate cancer (Thompson, Timme, Park, Yang,
& Ren, 2000). The cells were cultured in Dulbecco’s Modified Eagle’s Medium
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(GIBCO, Gaithersburg, MD, USA) completed with 10% bovine calf serum (BCS;
Hyclone Laboratories, Logan, UT, USA), 10 mM HEPES buffer, penicillin (100 RJ/ml),
and streptomycin (10 mg/ml) at 37°C in a humidified atmosphere containing 5% CO2.

Tumor Induction and Measurement
Prior to in vivo implantation, cells were harvested with 0.025% trypsin, washed in
PBS, and counted using the trypan blue exclusion method. Counts were adjusted to 5 x
106 cells/ml and 0.1ml (5 xlO5) was injected subcutaneously (s.c.) in the right hind flank
of the respective mice on designated day 0. The height (H), width (W), and length (L) of
tumors were measured using vernier calipers; volume was calculated using a formula that
approximates a hemi-ellipsoid: (H x W x L)/2.

MnTE-2-PyP Treatment
MnTE-2-PyP (Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin) was
synthesized by Ricerca Biosciences, LLC, Concord, Ohio, following procedures
previously described (Batinic-Haberle, et ah, 1999; Thompson, et ah, 2000). Drug
treatment of the relevant groups commenced on day 1 after RM-9 cell implantation and
was administered s.c. at a dose of 6 mg/kg body mass. Treatment continued daily for a
total of 12-16 days. Groups that did not receive drug were injected with equivalent
volumes of phosphate buffered saline (PBS) to maintain equivalent handling. The
time/dose schedule for administration of the drug was based on our previous studies
(Gridley, et ah, 2007).
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Tumor Irradiation
Radiation was delivered on day 7, the time at which the tumor was palpable. Mice
were anesthetized by intraperitoneal (i.p) injection of ketamine (80 mg/kg) and xylazine
(5.2 mg/kg); all animals (including controls with no tumor) received anesthetic,
regardless of irradiation, in order to equalize stress factors. Metal alloy blocks were
placed to shield the rest of the body so that only the tumor and underlying leg tissue was
irradiated. A 0.5 cm bolus was laid on top of each tumor to achieve electronic
equilibrium. Tumors received a single fraction of 10 gray (Gy) at a dose rate of ~0.8
Gy/min. Irradiation was done using a 60Co source and an Eldorado Model ‘G’ yirradiation machine (Atomic Energy of Canada Ltd, Commercial Products Division,
Ottawa, Canada).

Blood and Tissue Collection
Whole blood was collected by cardiac puncture with syringes containing K2EDTA. Plasma was obtained by micro-centrifugation at 4,000 g for 5 min and stored at 80oC. Spleens were also collected, weighed, and homogenized into single cell
suspensions in complete RPMI 1640 medium as previously reported (Gridley, et al.,
2007). Spleen mass relative to body mass (RSM) was calculated: RSM = organ mass
(mg)/body mass (g).

Hematological and Flow Cytometry Analyses
An automated hematology analyzer (HESKA, Waukesha, WI, USA) was used to
quantify white blood cells (WBC), major leukocyte populations, platelets, hemoglobin
(HGB) concentration and red blood cells (RBC), mean corpuscular volume (MCV,
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average RBC volume), mean corpuscular hemoglobin (MCH, average mass of HGB per
RBC), mean corpuscular HGB concentration (MCHC, average HGB concentration per
RBC), RBC distribution width (RDW, width of RBC based on cell number x cell size),
and mean platelet volume (MPV, average platelet size) (Miller, Andres, & Gridley,
2003). To quantify specific lymphocyte populations, WBC were labeled with CD45 for
leukocyte identification, followed by fluorescence-labeled monoclonal antibodies
(Pharmingen, San Diego, CA, USA) against CD3, CD4, CDS, CD19, and NK1.1 markers
for identification of total T, T helper (Th), T cytotoxic (Tc), B, and natural killer (NK)
cells, respectively. Samples were evaluated with a four-color FACSCalibur™ flow
cytometer (Becton Dickinson, Inc., San Jose, CA, USA) and 5,000-10,000 events were
analyzed with CellQuest Software version 3.1 (Becton Dickinson).

Spleen Leukocyte Analyses
An aliquot of each splenocyte suspension was run through an automated
hematology analyzer, (HESKA) to quantify total and major leukocyte populations as
described previously (Miller, et ah, 2003). Erythrocytes in the splenocyte suspensions
were then lysed and analyzed for T, Th, Tc, B, and NK cells by flow cytometry as
described above for blood lymphocytes.

TGF-pl and VEGF Quantification in Plasma
The active plus latent forms of TGF-pl and VEGF were quantified using
commercial enzyme-linked immunoassay (ELISA) kits (Quantikine; R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s instructions. The optical
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density was read at 450 nm with a correction wavelength of 570 nm using a microplate
reader (Infinite™ 200 series, Tecan, San Jose, CA, USA). Concentrations (pg/ml) were
calculated using the appropriate standards provided by the manufacturer.

IL-2 Quantification in Spleen Supernatants
Briefly, single-celled suspensions of splenic leukocytes at 2 x 106/ml were
activated with immobilized anti-CD3 (BioCoatTM anti-CD3 T Cell Activation Plates,
BD Pharmingen, San Diego, CA, USA). After a 48 h incubation, supernatants were
collected and IL-2 was quantified by Luminex-based bead array method using the
LINCOplex detection system (Linco Research, Inc., St. Charles, MO) following the
manufacturer’s instructions.

Statistical Analysis
The data from in vitro analyses were evaluated using one-way analysis of variance
ANOVA) followed by Tukey’s HSD (honestly significant difference) pairwise multiple
comparison test, if indicated. Two-way ANOVA was used to evaluate tumor
progression, with group and time as the independent variables. Data are reported as
mean± standard error of the mean (SEM). The Kaplan-Meier method was used to detect
association between treatment received and survival; where the endpoint examined was
the time interval beginning on the day of RM-9 cell implantation and ending when the
tumor reached a volume of ~ 2,000 mm3. A P < 0.05 indicated significance, whereas P <
0.1 was selected to indicate a trend.
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Results
Body Mass and Relative Spleen Mass (RSM)
All mice, either with or without tumor, survived for >12 days after inoculation
with RM-9 cells. Mice in all tumor-bearing groups weighed more than the non-tumor
bearing controls on days 7-8, but the difference was transient. At the time of euthanasia
for in vitro analyses (day 12), body mass ranged from 23.2± 0.5 g (Drug + Radiation) to
25.6± 0.4 g (No tumor). However, at this same time point, the groups receiving either
drug alone or radiation alone had increased spleen mass relative to body mass compared
to the control mice with no tumor (P < 0.05). Mean RSM values were 34.1± 2.7 (No
tumor), 42.2± 1.2 (No treatment), 46.0± 1.2 (Drug), 45.1± 4.0 (Radiation), 37.6± 2.5
(Drug + Radiation).
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Table 2. T lymphocyte subpopulations in blood. Values represent meant SEM for n = 810 mice/group. Data were obtained using fluorescent monoclonal antibodies and flow
cytometry. aP < 0.05 vs. No treatment and Drug; bP < 0.05 vs. No tumor, No treatment,
and Drug; CP < 0.05 vs. No tumor and No treatment; dP < 0.05 vs. all non-irradiated
groups; eP < 0.05 vs. No tumor.
Groups
Tumor
Cells and
Ratio

No
tumor

No
treatment

Drug

Radiation

Drug+
Radiation

CD4+ Th
(106/mm3)

1.11±0.15

1.21±0.14

1.25±0.13

0.72±0.10a

0.60±0.09b

CD8+ Tc
(106/mm3)

0.87±0.10

0.87±0.11

0.79±0.09

0.47±0.06c

0.44±0.06d

CD4:CD8

1.23±0.12

1.43±0.09

1.59±0.06

1.79±0.08c

1.70±0.08e
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Table 3. Summary of erythrocyte and platelet characteristics. Values were obtained with
an automated hematology analyzer and represent mean± SEM for 8-10 mice/group.
RBC, red blood cell count; RGB, hemoglobin; HCT, hematocrit; MCH, mean
corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV,
mean corpuscular volume; RDW, RBC distribution width; PLT, platelet count; MPV,
mean platelet volume. aP < 0.05 vs. No treatment; bP < 0.1 vs. No treatment; CP < 0.001
vs. Drug
Groups
Tumor
Test

No
tumor

No
treatment

Drug

Radiation

Drug +
Radiation

RBC
(106/mm3)

8.75±0.19

9.08±0.17

8.67±0.16

8.22±0.28a

8.61±0.22

RGB
(g/dl)

13.0±0.32

13.7±0.24

13.0±0.25

12.4±0.46b

12.9±0.31

HCT
(%)

39.8±0.99

41.6±0.79

39.7±0.75

37.7±1.36b

39.3±1.03

MCH
(Pg)

14.9±0.07

15.1±0.07

15.0±0.13

15.1±0.07

15.0±0.10

MCHC
(g/dl)

32.6±0.11

32.8±0.14

32.8±0.21

32.9±0.08

33.0±0.16

MCV
(pm3)

45.5±0.19

45.8±0.20

45.8±0.13

45.7±0.15

45.6±0.16

RDW
(%)

14.9±0.15

14.9±0.21

14.5±0.14

15.4±0.19c

14.7±0.17

PLT
(105/mm3)

843.4±29.98

929.9±23.87

901.1±41.34

892.1±46.39

893.7±25.62

MPV
(pm3)

10.1±0.20

9.9±0.21

9.7±0.29

9.6±0.14

9.7±0.20
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Table 4. T lymphocyte subpopulations in spleen. Values represent mean ± SEM for n =
8-10 mice/group. Data were obtained using fluorescent monoclonal antibodies and flow
cytometry. aP < 0.05 vs. No treatment and Drug; bP < 0.05 vs. No tumor, No treatment,
and Drug; CP < 0.05 vs. No tumor and No treatment; dP < 0.05 vs. all non-irradiated
groups; eP < 0.05 vs. No tumor.
Groups
Tumor
Cells and
Ratio

No
tumor

No
treatment

Drug

Radiation

Drug +
Radiation

CD4+ Th
(106/mm3)

2.75±0.51

3.92±0.26

4.97±0.4a

2.09±0.53b

1.17±0.3b

CD8+ Tc
(106/mm3)

1.53±0.28

2.48±0.16

2.99±0.3a

1.09±0.28b

0.72±0.2b

1.82±0.05

1.59±0.06

1.74±0.06

2.05±0.1c

1.96±0.1d

CD4:CD8
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Tumor Volume and Survival Analyses
As shown in Figure 10, mice in the Radiation and Drug + Radiation groups had
the slowest tumor progression. Tumor volumes in the Drug + Radiation group were not
significantly different versus the Radiation group. A slightly lower tumor volume was
observed in the group treated with drug alone compared to the non-treated controls.
Although, there was no significant difference in survival time between the Radiation and
the Drug + Radiation groups, Figure 11 shows that the fraction of surviving mice in the
Drug + Radiation group was higher across the entire length of the study. By day 18 there
were 0% survivors in the non-treated group, whereas in the Drug, Radiation and Drug +
Radiation groups there were 10%, 58%, and 85% survivors, respectively.
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WBC, Major Leukocyte Populations, and Lymphocyte Subpopulations
in Blood
Leukocytosis due to a dramatic increase in granulocytes was observed in the nontreated and drug only (tumor-bearing) groups when compared with non-tumor bearing
controls and irradiated groups (P < 0.05) (Figure 12). On the other hand, the two groups
that received radiation did not exhibit elevation in any leukocyte population. Similar
patterns were observed in all three cell types (lymphocytes, monocytes, and
granulocytes), regardless of drug treatment.
Figure 12 shows the effect of treatment on lymphocyte populations in the blood.
Although a decrease in T cells was noted in both irradiated groups, significance was
observed only versus the non-treated controls (P < 0.05). B cells were elevated in the
drug only group, and this increase was significant when compared to all other groups (P <
0.01). Radiation caused a significant decrease in NK cells when compared to all other
groups (P < 0.01).
Further analysis of the T cell subpopulations in blood showed a significant
radiation effect on both the CD4+ Th and CD8+ Tc cells (Table 2). Radiation alone
reduced the Th population in comparison to non-treated mice and those given drug alone,
whereas Tc cells were lower than in the No tumor, No treatment groups (P < 0.05). Drug
plus radiation treatment significantly reduced both the Th and Tc cell counts versus the
No tumor group; some differences were also noted compared to one or more of the
tumor-bearing groups (P < 0.05). The CD4:CD8 ratio was elevated in the group receiving
only radiation compared to the No tumor and No treatment groups, whereas the mice
treated with both drug and radiation had an increased ratio compared only to the No
tumor group (P < 0.05).
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RBC and Platelets in Blood
As shown in Table 3, the presence of tumor, treatment with radiation and/or drug
caused relatively few perturbations in RBC characteristics. Radiation alone decreased the
RBC count (P < 0.05) and there was a trend for low hemoglobin and hematocrit
compared to one or more of the other groups. RBC distribution width (RDW) in the
irradiated group receiving no drug was increased compared to drug alone (P < 0.05).
There were no significant differences among groups in platelet counts or volume.

WBC, Major Leukocyte Populations, and Lymphocyte Subpopulations
in Spleen
Leukocyte counts in the spleen showed a significant increase associated with
tumor presence (Figure 13). However, radiation in combination with the drug induced a
significant decrease in the WBC when compared to non-irradiated tumor-bearing groups
(P < 0.05). This same pattern was noted for the granulocytes and to a lesser extent also
for lymphocytes. Monocyte/macrophage counts were similar among all groups except
the one receiving drug plus radiation treatment, which had significantly reduced counts
versus the non-irradiated groups with tumor (P < 0.05).
Specific lymphocyte populations in the spleen are shown in Figure 13. In tumor
bearing mice, drug alone significantly increased T cell numbers compared to the No
tumor and both irradiated groups (P < 0.05). Significant drug-induced enhancement of B
cells and NK cells was also noted. In addition, both irradiated groups had lower T cell
counts versus the two non-irradiated groups with tumor and B cell numbers were
depressed in mice with non-treated tumor (P < 0.05).
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Lymphocyte subpopulation data are presented in Table 4. CD4+ Th and CD8+ Tc
cell counts were highest in the group receiving drug alone (P < 0.05 versus No tumor and
both irradiated groups). Radiation, either with or without drug, resulted in decreased
numbers of these cells compared to the two non-irradiated groups with tumor (P < 0.05).
A significant increase in the CD4:CD8 ratio was noted for the group receiving only
radiation compared to the non-treated group (P < 0.05).
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TGF-pi and VEGF in Plasma
No significant difference was observed in TGF-pl (latent plus active forms)
regardless of tumor presence or treatment (Figure 14). However, a trend (P < 0.1) for an
increase was observed in the group receiving only radiation in comparison to No tumor
and No treatment groups. A significant interaction for TGF-pl was observed with twoway ANOVA between radiation and drug treatment (P < 0.05). In contrast, the groups
that received radiation expressed significantly elevated levels of VEGF in comparison
with the No tumor and non-irradiated groups (P < 0.05) (Figurel5). Treatment with drug,
either alone or in combination with radiation did not show a significant effect on VEGF
expression.

IL-2 Production by Splenocytes
The level of IL-2 production in response to anti-CD3 activation was consistently
higher in the groups with tumor compared to the non-tumor-bearing control (Figure 16).
A significantly higher level was obtained in the group receiving drug alone compared to
the control group with no tumor and the tumor-bearing group receiving both the drug and
radiation (P < 0.05).
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Drug; + P < 0.05 vs. Drug + Radiation; f P < 0.05 vs. Radiation
and Drug + Radiation; ## P < 0.05 vs. all other tumor-bearing
groups.
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Figure 14. TGF-P in plasma. The data were obtained using ELISA
procedures.
Each bar represents mean± SEM for n=8-10
mice/group. $ P < 0.05 vs. no tumor; * P < 0.05 vs. non-irradiated
tumor-bearing groups; f P < 0.05 vs. irradiated groups. For
Radiation versus No Tumor and No treatment groups, the p value
was <0.1.
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Figure 15. VEGF concentrations in plasma. The data were
obtained using ELISA procedures. Each bar represents meant
SEM for n=8-10 mice/group. J P < 0.05 vs. no tumor; * P < 0.05
vs. non-irradiated tumor-bearing groups; f P < 0.05 vs. irradiated
groups. For Radiation versus No Tumor and No treatment
groups, the p value was <0.1.
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Figure 16. IL-2 concentration in activated spleen cell supernatants
The data were obtained using an ELISA procedure after activation
with anti-CD3 monoclonal antibody. Each bar represents mean ±
SEM for n=8-10 mice/group. J p<0.05 vs. No tumor; + p<0.05 vs.
Drug + Radiation.
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Discussion
As it has already been established that antioxidant mimetic compounds can protect
normal tissues against radiation damage (Vujaskovic, et ah, 2002) a main question was:
Does MnTE-2-PyP protect tumors and if not, why? The data presented here demonstrate
that tumor volumes were significantly reduced by radiation regardless of drug treatment.
Although there was no statistically significant difference between the Radiation and Drug
+ Radiation groups, the rate of tumor growth was slowest in the group receiving both
treatments (i.e., more mice survived with tumor volumes </=2000 mm3 by the end of the
study). These data show that MnTE-2-PyP does not protect tumor against radiationinduced damage in this pre-clinical model of prostate cancer.
The immunodepressive effect of radiation was exhibited by low levels of the three
major leukocyte populations (lymphocytes, monocytes and granulocytes) in the blood.
Similar findings were also noted in the spleen, but with a less pronounced outcome. This
radiation effect was comparable regardless of drug treatment, signifying that MnTE-2PyP did not exacerbate the radiation-induced decrease in any of these white blood cell
types. Furthermore, the depressive effect of radiation on RBC counts, hemoglobin, and
hematocrit and increase in RBC distribution width did not occur when the drug was used
together with radiation. This latter finding suggests that risk for anemia associated with
radiation therapy may be minimized by administration of MnTE-2-PyP. A recent review
concluded that low hemoglobin and/or a high level of tumor hypoxia correlated with a
poor prognosis for patients with prostate and other types of cancers (Varlotto &
Stevenson, 2005). The few and transient differences in body mass observed among our
experimental groups, as well as maintenance of near-normal activity by the treated mice,
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support the conclusion that health was not seriously compromised by the treatment
regimens. These are all important observations, since different forms of therapy,
especially when used concurrently, can sometimes cause unexpected and severe
toxi cities.
Although MnTE-2-PyP did not significantly affect radiation-associated changes in
the distribution of specific leukocyte populations at the time of assessment, there were
some striking elevations in certain cell types when the drug was used alone. The highest
levels of total CD3+ T, CD4+ Th and CD8+ Tc lymphocytes were found in the spleens
from the group receiving only MnTE-2-PyP, while a normal CD4:CD8 ratio was
maintained. These cells have long been known to be of great importance in tumor
destruction by direct cell-to-cell contact and regulation of anti-tumor immune responses
by virtue of the cytokines they secrete. The exceptionally high level of IL-2, a Thl cellderived cytokine, secreted by activated splenocytes in the group treated with MnTE-2PyP suggests that these cells are able to respond well. IL-2 is essential for optimal T cell
activation and subsequent expression of their cytotoxic and helper activities. Indeed,
convincing evidence that cancers of the prostate and other body sites can be
immunogenic have led to clinical trials with vaccines, some of which include IL-2 (Arlen
PM, 2005; Brill, et al., 2007). However, tumors evade and/or suppress the immune
system in a variety of ways such as down-regulation of tumor antigens, impairment of
antigen presentation, and secretion of immunosuppressive cytokines (Croci, et al., 2007).
Reports indicate that treatment with antioxidants can diminish the immune
evasion/suppression mediated by tumor cells (Malmberg, 2004) and cause them to lose
their “altered phenotype” (Valko, et al., 2007). Therefore, it seems possible that by
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scavenging for ROS, MnTE-2-PyP may modify the pathways by which tumors evade the
immune system.
The drug-induced increase in the splenic NK cell population is a response that
should not be overlooked. These cells play an important role in innate immunity and have
the ability to recognize and eradicate tumor cells, as well as virus-infected and other
aberrant cells, by detecting phenotypic changes on the target (Cerwenka & Lanier, 2003;
Scott, Meade, & Cook, 2008). NK cell activation is dependent on a balance between
inhibitory and activation signals and the ability to discriminate between normal and
tumor cells based on differences in major histocompatibility complex (MHC) class I
expression. The MHC-specific inhibitory receptors on the surface of NK cells recognize
loss of expression on tumor cell surfaces, leading to a failure of receptors to deliver
inhibitory signals (Scott, et ah, 2008). Additionally, a number of ligands present on
tumors are recognized by receptors on NK cells that trigger activation signals (Pende, et
ah, 2001; Scott, et ah, 2008) that, together with failure to deliver inhibitory signals, shift
the balance towards NK-mediated tumor cell death.
Interestingly, significant elevation of B cells was observed in both the blood and
spleens from mice treated only with MnTE-2-PyP compared to all other groups. B cells
are a critical component of the immune system in that they respond to antigens with the
production of antibodies and secretion of cytokines (Lee, 2003; Zinkemagel, 2000).
Although optimal B cell activation is often thought to require T cell help, elevation in
these cells can also occur via a T cell-independent pathway (Bergamin, Vincent,
Summerfield, & McCullough, 2007; Craxton, Magaletti, Ryan, & Clark, 2003; ShulgaMorskaya, et ah, 2004). CD40, a member of the TNF-receptor superfamily expressed on
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the surface of Th cells (Rakhmilevich, Buhtoiarov, Malkovsky, & Sondel, 2008), has
been recently found also on B cells and is associated with T cell-independent B cell
activation (Lee, 2003). Ligation with CD40L on dendritic and other antigen-presenting
cells (APC) activates B cells and induces their proliferation, survival, and differentiation
(Bergamin, et ah, 2007). In addition, APC produce B cell-activating factor (BAFF), a
ligand in the TNF family that promotes generation and survival of mature B cells, can
induce activation independently of T cells (Shulga-Morskaya, et al., 2004). It may be
that MnTE-2-PyP up-regulates one or more of the above processes.
Furthermore, ROS have been reported to play a variety of roles in B cell
activation, proliferation, survival, and maintenance (Lee, 2003). ROS elevation can lead
to oxidative stress that hinders cell proliferation and death (Moon, et al., 2006; Tohyama,
Takano, & Yamamura, 2004). Liu et al. have reported on the suppressive effect of ROS
on CD40-induced B cell activation (Liu, Yoshida, & Yamashita, 2007). In contrast,
tumors require appreciably higher levels of ROS to support their survival. In tumor
metabolism, ROS can promote carcinogenesis, metastasis, survival and progression
(Storz, 2005; Wu, 2006). Thus, while tumor cells would be negatively affected by MnTE2-PyP due to their dependence on elevated oxidative stress (Andarawewa, Paupert, Pal, &
Barcellos-Hoff, 2007), B cells could, on the other hand, be enhanced by reduction of
ROS (Wu, 2006).
As expected, the highest level of plasma TGF-pl was found in the group receiving
radiation alone and a trend for enhancement was noted compared to the No tumor and No
treatment groups. This factor is up-regulated by radiation and is associated with late
radiation effects such as fibrosis, increased tumor resistance to radiation, and suppression
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of anti-tumor immunity (Andarawewa, et al., 2007; Bommireddy & Doetschman, 2007).
Although statistical significance was not obtained, TGF-pl concentration was closer to
normal when MnTE-2-PyP was combined with radiation. This latter finding, if confirmed
in future studies, would be consistent with the drug-induced enhancements we have noted
here in IL-2 production and certain immune cell populations. Lack of statistical
significance in our study may be related to the up/down fluctuations that are known to
occur in TGF-pl with time after radiation.
Although we did not see an effect of MnTE-2-PyP on circulating VEGF
concentration in the mice receiving radiation treatment, a highly significant increase was
observed in both irradiated groups. The lack of a significant decrease in VEGF that
regulates angiogenesis, as we originally expected based on hypoxia inducible factor-la
(HIF-la) data in our previous study with a different metalloporphyrin antioxidant
(Gridley, et al., 2007), might be due to the fact that ROS are not the only molecules that
can enhance its production. It is also possible that the absence of a drug effect on VEGF
is related to differences in metalloporphyrin antioxidant efficacies in mediating a
particular effect. Another possibility is that the plasma level of VEGF at the time of
assessment may not necessarily reflect the level of the factor within the tumor mass itself.
Although our focus was on treatment-related changes in leukocyte populations and
cytokines that can affect tumor growth, it should be pointed out that presence of the RM9 tumor, without any treatment, caused at least two significant changes. A dramatic
increase in granulocytes was seen in both blood and spleens from the non-treated tumor
bearing group, an enhancement that remained evident also in the group given only
MnTE-2-PyP. This finding suggests that the RM-9 tumor cells may secrete a factor that
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stimulates granulopoiesis. In contrast, B cell numbers in the spleens from these mice
were significantly below normal, an effect that was counteracted by MnTE-2-PyP as
discussed above. The underlying mechanisms responsible for these tumor-induced
aberrations remain to be elucidated.

Conclusion
Our results show that administration of MnTE-2-PyP together with radiation did
not enhance RM-9 tumor growth, thus demonstrating that the drug does not protect
tumors against radiation in this prostate tumor model. There were no observed adverse
effects due to addition of MnTE-2-PyP to radiation treatment. Instead, the drug
normalized several RBC parameters that differed significantly from normal in the
animals receiving radiation.
The drug did not have a statistically significant effect on tumor volume when used
alone or together with radiation. Nonetheless, the slowest tumor growth occurred in the
group treated with both modalities. Furthermore, the group receiving MnTE-2-PyP had
relatively high levels of T, Th, Tc, and NK cells in the spleen, high B cell counts in both
blood and spleen, and high capacity to produce IL-2. These findings support the
possibility that the drug has potential to enhance anti-tumor immune responses. In
addition, increased ROS levels of many cancers is associated with altered signaling
pathway regulation by which tumors escape cell death, increase proliferation and
evade/suppress immune recognition. When ROS are scavenged, tumor cells can no
longer maintain their altered phenotype and the mechanisms they utilize to enhance
survival, progressive growth, and evasion of immune-mediated death.
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In summary, we propose that MnTE-2-PyP may be useful not only as a normal
tissue radioprotectant based on its ability to scavenge ROS, but may also serve to
enhance mechanisms that are vital for effective immune responses against neoplastic
cells and decrease risk for anemia in patients undergoing radiotherapy. The data reported
here are unique and should stimulate further research with metalloporphyrin antioxidants.
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Abstract
The goal of this study was to evaluate cytokine secretion capacity in a mouse
model of prostate cancer, both with and without metalloporphyrin antioxidant and
radiation treatment. The data are from C57BL/6 mice with subcutaneous RM-9 tumor
treated daily for 12 days with MnTE-2-PyP [Mn (III) tetrakis (N-ethylpyridinium-2-yl)
porphyrin], beginning 1 day after RM-9 cell injection; a 10 Gy tumor-localized dose of yrays (Co-60) was administered in a single fraction on day 7. Spleen, tumors, and plasma
were collected on day 12. T cells in spleen were activated with anti-CD3 antibody and
supernatants were collected. Twenty-two cytokines were quantified in spleen
supernatants, five in tumor homogenates, and three in plasma utilizing multiplex bead
array technology and ELISA. Presence of tumor had significant effects on many of the
quantified cytokines (P < 0.05). Tumor-induced depression was evident for eight spleen
cytokines (TNF-ot, G-CSF, GM-CSF, IFN-y, IL10, IP-10, MIP-la, and mKC), whereas
only three were enhanced (ILip, IL6, and MCP-1). Radiotherapy resulted in enhanced
splenocyte capacity to produce IL4 and IL13 and increased IL4, MCP-1, and VEGF in
tumors {P < 0.05). Addition of MnTE-2-PyP to radiation decreased concentrations of
IL4, IL13, and TGF-pl in spleen supernatants and IL4 and VEGF in tumors (P < 0.05 vs.
radiation alone). Some differences were also noted in plasma cytokines. Overall, the
findings suggest that administration of MnTE-2-PyP together with radiotherapy may
enhance anti-tumor immune responsiveness and decrease the risk for radiation-induced
normal tissue toxicities.
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Introduction
Radiation therapy is immensely significant in curative and adjuvant cancer
treatment; however, its benefits to patients are diminished due to normal tissue toxicity.
Dose determination is critical and often poses a clinical dilemma. In prostate cancer
treatment, determination of an optimal radiation dose still poses a major challenge, as
higher radiation doses increase the risk of urinary and rectal toxicities (Zelefsky, et al.,
2006b). Patients have been shown to have an increased rate of severe complications
when more than 25% of the rectum was irradiated at doses >70Gy. Complications include
chronic proctitis, rectal bleeding, increased urinary frequency, urethral stricture,
impotence, and gastrointestinal problems (Hanks, Coia, & Curry, 1997; Hanks, Martz, &
Diamond, 1988; Smalley, 1989; Storey, et al., 2000). In addition, higher dose levels have
the potential for increasing the risk for secondary neoplastic disease (Wu, et al., 1999)
and long-term morbidity. Dose optimization is essential and required in order to achieve
maximum tumor destruction with minimal damage to normal tissue. Currently emerging
trends in prostate cancer treatment include combination of radiation and drug therapy
(Lee & Stupans, 2002).
Antioxidants are well established as normal tissue radioprotectants and have great
potential in the clinical setting for cancer treatment in combination with radiotherapy;
however, to be useful, they must not protect tumors from radiation. Superoxide dismutase
(SOD) catalyzes the dismutation of superoxide,

, into hydrogen peroxide (H2O2).

Catalase (CAT) and glutathione peroxidase (GPX), in turn, catalyze the H2O2 into H2O
and O2. These antioxidants effectively protect cells against oxidative stress including
radiation-induced toxicity (Fridovich, 1995).
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Mn(III) tetrakis(N-ethylpyridinium-2-pyridyl) porphyrin (MnTE-2-PyP) is a
superoxide dismutase mimetic (SODm). As a metalloporphyrin, it is a small and stable
non-peptide, properties which improve its potency and sustain its ability to overcome the
limitations associated with bovine or recombinant SOD such as their short half-lives,
poor cell delivery, antigenicity/hypersensitivity and cost (Salvemini, et ah, 2002). Most
importantly, these types of drugs have a redox-active metal center that functions similarly
to naturally occurring SODs in dismutation O2". In addition to their roles as SODm, they
function as broad spectrum antioxidants, scavenging other free radicals such as H2O2 Hpid
peroxides and reactive nitrogen species (RNS), i.e. nitric oxide(NO), peroxynitrite
(ONOO-) and the carbonate radical (CO3.) (Ferrer-Sueta, et ah, 2002; Ferrer-Sueta, et ah,
2003; Spasojevic, et ah, 2000). Their antioxidant abilities to protect against ROS-induced
toxicities have been well established in disease models of stroke (Bowler, et ah, 2002;
Shimizu, et ah, 2003), diabetes (Haskins, et ah, 2003), sickle cell anemia (Kaul, et ah,
2006), Parkinson’s disease, amyotrophic lateral sclerosis (Melov, et ah, 1998; Traynor, et
ah, 2006), asthma (Chang & Crapo, 2002; Masini, et ah, 2005) and chronic inflammation
(Smith, et ah, 2002; Tse, Milton, & Piganelli, 2004). Their radioprotective effects have
also been demonstrated in irradiated lungs (Rabbani, Salahuddin, et ah, 2007). In addition
to protecting normal tissues against radiation-induced damage, our previous studies have
shown possible anti-tumor effects of MnTE-2-PyP and MnTDE-2-ImP (manganese (III)
meso-tetrakis (l,3-diethylimidazolium-2-yl) porphyrin). Most recently, reports have
demonstrated SODm to also have anti-tumor properties (Gridley, et ah, 2007; Makinde,
et ah, 2009; Moeller, et ah, 2005b), making their use more significant as this property has
the potential of enhancing radiotherapy in cancer.
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The immune system is a key player in defense against tumors. However, a major
challenge is distinguishing antigens on malignant cells from those on normal self cells.
Tumors result from a dynamic shift in the delicate balance of intrinsic pathways
involving oncogenes and tumor suppressors following external stimuli (such as
carcinogenic agents) or the dysregulation of extracellular pathways (such as chronic
inflammation). Tumor presence promotes activation of pathways that would enhance its
survival and proliferation while inhibiting those making it more susceptible to cell death,
controlled proliferation, and immune recognition. Cytokines play a major role in a variety
of these pathways, ranging from altering immune response, apoptosis/cell death, cellular
proliferation, differentiation, and inflammation.
In our previously published study, treatment with MnTE-2-PyP did not modify
tumor growth significantly {24). However, there were significant increases in T, B, and
natural killer (NK) cell populations in spleens from MnTE-2-PyP treated mice with tumor
(Makinde, et al., 2009). Since all of these leukocyte types secrete cytokines that can
affect immune responsiveness against tumors and an increase in IL2 secretion was also
noted {24), we wanted to further explore the effect of this normal tissue radioprotectant
on cytokine production. Thus, the major purpose of the present study was to assess
cytokine profiles in the groups that had received the drug, with and without tumorirradiation, and to identify significant alterations. Although relationships among radiation
response, ROS production, and cytokines have long been established, the effect of these
types of drugs on cytokines and tumor progression is not yet fully understood.
Investigating the systemic effect of this drug on cytokine profiles in the context of tumorlocalized irradiation could help identify potential pathways of action that might have
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previously been overlooked. Our overall aim was to evaluate cell cytokine profiles and
correlate the data with our previously published tumor volume and leukocyte data
(Makinde, et ah, 2009).

Materials and Methods
Animals
Eight to 9 week old male C57BL/6 mice (n = 48) were purchased from Charles
River Breeding Laboratories Inc. (Hollister, CA) and acclimatized for about one week
prior to initiation of study. They were housed individually under identical conditions of
standard temperature, humidity and 12-h light/dark cycling. Food and water were
provided ad libitum. The mice were weighed and observed periodically for signs of
toxicity. Rapid CO2 euthanasia was performed under the approved IACUC protocol and
in compliance with recommendations in the NIH Guide for the Care and Use of
Laboratory Animals.

Treatment Groups
Animals were randomly assigned to 5 groups (n = 8-10/group) based on treatment
received. A No tumor control group was designated to serve as the baseline for in vitro
analyses; all other animals were tumor-bearing and grouped as follows: i) No treatment;
ii) Drug only; iii) Radiation; and iv) Combination (drug + radiation). Animals were
euthanized 12 days after tumor induction.
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Tumor Cell Line
RM-9 is a prostate cancer cell line that was originally derived from a ms + myc
transformed/wild-type p53 primary prostate tumor induced in the Zipras/myc-9-infected
mouse prostate reconstitution (MPR) model using C57BL/6 mice. This cell line has been
extensively characterized for pathological and phenotypic properties and was selected
because of its close similarity with human prostate cancer (Thompson, et ah, 2000).
Cells were cultured in DMEM (GIBCO, Gaithersburg, MD) completed with 10%
bovine calf serum (BCS; Hyclone Laboratories, Logan, UT), 10 mM HEPES buffer,
penicillin (100 lU/ml), and streptomycin (10 mg/ml) at 37°C in a humidified atmosphere
containing 5% CO2.

Drug Treatment
MnTE-2-PyP [Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin] was
synthesized by Ricerca Biosciences, LLC, Concord, OH. Treatment of the relevant
groups commenced one day after RM-9 cell implantation (dayl) and was administered
i.p. at a dose of 6 mg/kg body mass. Treatment continued daily for a total of 12 days.
Groups that did not receive drug were injected with equivalent volumes of PBS to
maintain equivalent handling. The time/dose schedule for administration of the drug was
based on our previous studies (Makinde, et al., 2009).

Tumor Cell Injection, Volume, and Irradiation
RM-9 tumor cells were cultured, harvested, and counted as previously described
(24). The cells were then adjusted to 5 x 106/ml in PBS and 0.1 ml (5 xl05 cells) was
injected s.c. in the right hind flank. The length (L), width (W), and height (H) of the
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tumors were measured using vernier calipers and volume was calculated: (H x W x L)/2.
Radiation was delivered on day 7, the point at which the tumor was palpable. Mice were
anesthetized by i.p. injection of ketamine (80mg/kg) and xylazine (5.2mg/kg). All
animals received anesthetic in order to equalize treatment and stress factors. Metal alloys
blocks were placed to shield the rest of the body as much as possible so that only the
tumor and the underlying leg tissue was irradiated. A 0.5 cm bolus was laid on top of
each tumor to achieve electronic equilibrium. Tumors received a single fraction of 10 Gy
at a dose rate of ~0.8 Gy/min. Irradiation was done using a 60Co source and an Eldorado
Model ‘G’ y-irradiation machine (Atomic Energy of Canada Ltd, Commercial Products
Division, Ottawa, Canada).

Blood and Tissue Collection
Whole blood was collected by cardiac puncture at the time of euthanasia with
syringes containing K2-EDTA. Plasma was obtained by micro-centrifugation at 4,000 g
for 5 min and stored at -80°C. Spleens were collected, weighed, and homogenized into
single cell suspensions in complete RPMI 1640 medium as previously reported (Gridley,
et al., 2007). Prostate tumor tissue was excised, weighed and homogenized in 1 mL
Dulbecco’s PBS (Mediatech) containing a cocktail of protease inhibitors (Roche,
Indianapolis, IN). Homogenized tumors were centrifuged at 3,000 rpm for 10 min,
aliquots of supernatants were stored at -80°C until analysis.

Splenocyte Quantification and Activation
Following lysis of red blood cells, an aliquot of each splenocyte suspension was
run through an automated hematology analyzer, (HESKA, Waukesha, WI) for
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quantification (Miller, et al., 2003). Splenic leukocyte counts were adjusted to 2 xlO6
cells/ml and 100 pi was dispensed per well in anti-Mouse CDS BioCoat™ T-Cell
Activation 96-well Assay Plates (BD Pharmingen, San Diego, CA). Total well volume
was adjusted to 200 pl/well with complete RPMI medium. A minimum of six wells were
used for activated and for inactivated cells per each sample. Supernatants were harvested
48 h after incubation (37°C) and stored at 80°C until immediately before analysis. This in
vitro approach with anti-CD3 was used to generate a robust T cell response that would
result in cytokine levels that could readily be quantified; an antigen-specific effect would
not be as pronounced.

Cytokine Analysis
Frozen spleen supernatants were rapidly thawed and a multiplex microbead-based
immunoassay (Linco Research, Inc., St. Charles, MO) was used to determine the
concentrations of 21 cytokines and chemokines as follows: G-CSF (Granulocyte ColonyStimulating Factor), GM-CSF (Granulocyte Macrophage-CSF), IFN-y (Interferon-y),
ILloc, ILlp, IL4, IL5, IL6, IL7, IL9, IL10, IL12, IL13, IL15, IL17, IP-10 (IFN-y Induced
Protein-10), MCP-1 (Monocyte Chemotactic Protein-1), MIP-la (Macrophage
Inflammatory Protein-la), mKC (Mouse Keratinocyte-derived Chemokine), RANTES
(Regulated upon Activation, Normal T-cell Expressed, and Secreted), and TNF-a (Tumor
Necrosis Factor-a). This panel was selected because it relates directly to immune
responsiveness, a wide range of factors could be efficiently quantified, and there was
essentially no pre-existing information on specific cytokines/chemokines that might be
modulated by MnTE-2-PyP. Active plus latent forms of TGF-pl(Transforming Growth
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Factor-pl), a potent inhibitor of lymphocyte and macrophage activities, were also
quantified in spleen supernatants using a commercial ELISA kit (Quantikine; R&D
Systems, Minneapolis, MN) according to the manufacturer’s instructions. The OD was
read at 450 nm with a correction wavelength of 570 nm using a microplate reader
(Infinite™ 200 series, Tecan, San Jose, CA). Concentrations (pg/ml) were calculated
using the appropriate standards provided by the manufacturer.
Based on changes in cytokine levels in spleen supernatants, several cytokines were
subsequently assessed in plasma and tumors. Frozen plasma samples were brought to
room temperature and concentrations of IL4, IL13, and MCP-1 were assessed with a
customized multiplex bead array kit (Linco Research). Following thawing of supernatants
from tumor homogenates the same three cytokines and vascular endothelial growth factor
(VEGF) were quantified using a similar multiplex array; TGF-pl was assayed with an
ELISA kit as described above for spleen supernatants.
The multiplex panels were specific for the mouse versions of these
cytokines/chemokines; the standard curve range was 3.2 to 10,000 pg/ml. Minimum
detectable level of TGF-pl by ELISA was 1.7 pg/ml.

Statistical Analysis
Data were evaluated using one-way ANOVA with group as the independent
variable followed by Tukey’s HSD (honestly significant difference) pairwise multiple
comparison test, if indicated. In addition, two-way ANOVA was done on all the tumor
bearing groups with drug and radiation as the independent variables. P < 0.05 indicated
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significance, whereas ^ < 0.1 was selected to indicate a trend. The data are presented as
the mean ± SEM.

Results
Tumor Volume
The tumor volumes obtained for the four groups over time after RM-9 cell
injection have been previously reported (24). Although addition of MnTE-2-PyP to
radiation did not result in significantly smaller tumor size at any time point of
measurement, the slowest growth was consistently seen in the group receiving
combination treatment. The data reported here are from mice euthanized on day 12 after
RM-9 cell injection. On day 12, tumor volumes in the Radiation and Drug+Radiation
groups (1,103 ± 56 mm and 1,022 ± 60 mm , respectively) were significantly lower (P <
0.05) compared to the No treatment and Drug alone groups (1,375 ± 66 mm3 and 1,299 ±
63 mm , respectively) (24).

Cytokines in Activated Splenocyte Supernatants
Nineteen (G-CSF, GM-CSF, IFN-y, ILla, ILlp, IL4, IL5, IL6, IL9, IL10, IL13,
IL17, IP-10, MCP-1, MIP-la, mKC, RANTES, TNF-a and TGF-pl) of the 22 spleen
cytokines were detectable according to the minimum detection value for each cytokine as
per the manufacturer’s protocols. IL7, IL12, and IL15 levels were not detectable.
Figure 17A shows that the level of IL4 was greatly increased in supernatants of
splenocytes from tumor-bearing mice treated with radiation alone; the mean for this
cytokine was significantly greater than for any of the other groups, including the one with
no tumor (P < 0.05 for Radiation versus all other groups). However, when MnTE-2-PyP
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was combined with radiation, IL4 level was decreased closer to normal and was
significantly lower than radiation alone (P < 0.05). Two-way ANOVA showed a
significant interaction between drug and radiation in tumor-bearing groups (P < 0.05).
Tumor presence did not have a significant effect on IL5 concentration in spleen
supernatants (Figure 17B). However, radiation alone or when combined with the drug did
significantly increase IL5 compared to the group with no tumor and the non-treated
tumor-bearing group (P < 0.05). A pattern somewhat similar to IL4 was found for IL13
(Figure 17C). The highest production of IL13 occurred in mice treated with radiation
alone and addition of the drug to radiation decreased the level closer to normal (P < 0.05
for Radiation versus Drug + Radiation). It should be noted that the group with nontreated tumor also had a lower level of IL13 compared to the tumor-bearing group
receiving radiation alone (P < 0.05). Figure 17D shows that TGF-pl secreted by activated
splenocytes was significantly decreased with the combination of MnTE-2-PyP and
radiation compared to the tumor-bearing groups that were non-treated or that received
radiation only (P < 0.05). A trend was observed for decreased TGF-pl concentration in
the drug only group versus the non-treated tumor-bearing group (P < 0.1).
In Figure 18 A, it can be seen that ILlp production by splenocytes from tumor
bearing groups receiving either no treatment or MnTE-2-PyP plus radiation was higher
than for the control group with no tumor (P < 0.05). Figure 18B shows that the level of
MCP-1 was increased for all four tumor-bearing groups compared to the one with no
tumor (P < 0.05). However, the tumor-bearing group that received treatment with both
modalities produced the greatest amount of MCP-1; the level was significantly higher
compared to both non-irradiated groups, i.e., the non-treated and drug alone groups (P <
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0.05). Figure 18C shows a significant decrease in TNF-a resulting from tumor presence
when mice were not treated or treated with drug alone (P < 0.05). Although radiation
caused a slight increase in this tumor-induced decrease, statistical significance was
observed only when the drug was used in combination with radiation (P < 0.05 versus No
treatment and Drug only).
Data obtained for eight cytokines that were either decreased or increased by tumor
presence, regardless of treatment, are shown in Figure 19. The levels of G-CSF, GMCSF, IFN-y, IL10, IP-10, MIP-la, and mKC in splenocyte supernatants were consistently
lower in all tumor-bearing groups compared to the group with no tumor (panels A-C and
E-H in Figure 19) (P < 0.05). In contrast, the level of IL6 was increased in all groups with
tumor (Figure 19D) (P < 0.05 versus No tumor). Treatment with MnTE-2-PyP, radiation,
or a combination of both had no statistically significant effect on production capacity for
any of these cytokines, except that an interaction was observed for mKC in the tumor
bearing groups after two-way ANOVA (P < 0.05).
Table 5 summarizes the proportion of the 15 significantly affected cytokines in
spleen supernatants obtained for the tumor-bearing groups in relation to the control group
with no tumor. In Table 6, the means and SEM are shown for the four cytokines that were
not significantly affected by either tumor presence or treatment (ILla, IL9, IL17, and
RANTES).
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Figure 17. Quantitative assessment of IL4, IL5, IL13, and TGF-(31 in
supernatants from activated splenocytes. A group without tumor was
designated as baseline control. Treatment was given as indicated.
Results are presented as the mean ± SEM for t? = 8-10 mice/group. *F> <
0.05 versus No tumor;
< 0.05 versus Radiation; #P < 0.05 versus
non-irradiated tumor-bearing groups (No treatment and Drug); +P <
0.05 versus No treatment and Drug+Radiation;; fP < 0.05 versus No
treatment, *P < 0.05 versus No tumor and No treatment; aP = 0.059
versus Radiation.
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Figure 17, continued. Quantitative assessment of IL4, IL5, IL13, and
TGF-{31 in supernatants from activated splenocytes. A group without
tumor was designated as baseline control. Treatment was given as
indicated. Results are presented as the mean ± SEM for n = 8-10
mice/group. *P < 0.05 versus No tumor; **F> < 0.05 versus Radiation;
#P < 0.05 versus non-irradiated tumor-bearing groups (No treatment and
Drug); +P < 0.05 versus No treatment and Drug+Radiation;; "fP < 0.05
versus No treatment, *P < 0.05 versus No tumor and No treatment; aP =
0.059 versus Radiation.
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Figure 18. Quantitative assessment of primary inflammatory cytokines
IL1(3, MCP-l, and TNF-a in activated splenocyte supernatants. A group
without tumor was designated as baseline control. Treatment was given
as indicated. Results are presented as the mean ± SEM for n = 8-10
mice/group. */* < 0.05 versus No tumor; #P < 0.05 versus non-irradiated
tumor-bearing groups (No treatment and Drug).

86

c

TNF-ot
500 n
450

#

400 ■
350
g 300
250
tUD
Q. 200
150
100

■
■
-

*

*

■

I

fm I
1

■
il

50 ■

.

0
No Tumor

No
Treatment

Drug

Radiation

Drug +
Radiation

Figure 18, continued. Quantitative assessment of primary inflammatory
cytokines ILlp, MCP-1, and TNF-a in activated splenocyte
supernatants. A group without tumor was designated as baseline control.
Treatment was given as indicated. Results are presented as the mean ±
SEM for n = 8-10 mice/group. *P < 0.05 versus No tumor; #P < 0.05
versus non-irradiated tumor-bearing groups (No treatment and Drug).
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Figure 19. Quantitative assessment of G-CSF, GM-CSF, IFN-y, IL6,
IL10, IP-10, MIP-la, and mKC from activated splenocyte supernatants.
A group without tumor was designated as baseline control. Treatment
was given as indicated. Results are presented as the mean ± SEM for n =
8-10 mice/group. *P < 0.05 versus No tumor; #P < 0.05 versus nonirradiated tumor-bearing groups (No treatment and Drug).
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Figure 19, continued. Quantitative assessment of G-CSF, GM-CSF,
IFN-y, IL6, IL10, IP-10, MIP-la, and mKC from activated splenocyte
supernatants. A group without tumor was designated as baseline control.
Treatment was given as indicated. Results are presented as the mean ±
SEM for 7? = 8-10 mice/group. *P < 0.05 versus No tumor; #P < 0.05
versus non-irradiated tumor-bearing groups (No treatment and Drug).
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IFN-y, IL6, IL10, IP-10, MIP-la, and mKC from activated splenocyte
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Figure 19, continued. Quantitative assessment of G-CSF, GM-CSF,
IFN-y, IL6, IL10, IP-10, MIP-la, and mKC from activated splenocyte
supernatants. A group without tumor was designated as baseline control.
Treatment was given as indicated. Results are presented as the mean ±
SEM for 7? = 8-10 mice/group. *P < 0.05 versus No tumor; #P < 0.05
versus non-irradiated tumor-bearing groups (No treatment and Drug).
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Cytokines in Plasma
The group receiving only radiation had decreased IL4 compared to the two nonirradiated tumor-bearing groups (P < 0.05) (Figure 20A). Tumor presence significantly
increased IL13 concentration, while treatment with MnTE-2-PyP either alone or together
with radiation led to significant decreases (Figure 20B). Radiation alone, however,
resulted in the lowest level of IL13 that differed significantly from both non-irradiated
tumor-bearing groups (P < 0.05). Figure 20C shows that tumor presence resulted in
significantly increased MCP-1 plasma concentration in all groups except the one
receiving radiation alone. The level of this cytokine in the radiation only group, although
still higher than in the group with no tumor, was significantly decreased compared to the
untreated tumor-bearing group (P < 0.05). When radiation was combined with the drug,
there was a trend for MCP-1 elevation above the level found for radiation alone (P < 0.1).
The proportions of these three cytokines in plasma from the tumor-bearing groups in
relation to the group with no tumor are shown in Table 5.
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Figure 20. Quantitative assessment of IL4, IL13, and MCP-1 in plasma.
A group with no tumor served as a baseline control. Treatment was
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Cytokines in Tumors
Figure 21A shows that IL4 concentration in tumors was significantly elevated in
the radiation only group compared to the group receiving only the drug (P < 0.05). In
combination with drug, the radiation-induced increase in IL4 was significantly decreased
versus radiation alone (P < 0.05). IL13 concentration in tumors was significantly lower in
the group treated with drug alone compared to the mice with non-treated tumor (P < 0.05)
(Figure 2IB). The drug, in contrast to what was seen with IL4, did not modify the level of
IL13 compared to the group receiving only radiation. Treatment with radiation resulted in
significantly increased MCP-1 in tumors compared to both non-irradiated tumor-bearing
groups (P < 0.05) and the addition of drug had no effect on the enhancement (Figure
21C). In contrast, although VEGF was also increased by radiation alone (P < 0.05 versus
both non-irradiated groups), its concentration was greatly reduced by addition of MnTE2-PyP (P < 0.05) (Figure 2ID). Treatment with the drug alone also decreased tumor
VEGF concentration compared to the non-treated tumor-bearing group (P < 0.05).
Although no significant difference was detected in tumor TGF-pl concentration among
groups, a trend was observed for a radiation-induced decrease (P = 0.075 versus no
treatment) (Figure 2IE).
Table 5 summarizes the proportion of these cytokines in the groups with treated
tumors in relation to the group with non-treated tumor.
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Figure 21. Quantitative assessment of IL4, IL13, MCP-1, VEGF, and
TGF-(31 in RM-9 tumors. Treatment was given as indicated. Each bar
represents the mean ± SEM for n = 8-10 mice/group. **F> < 0.05 versus
Radiation; #P < 0.05 versus non-irradiated tumor-bearing groups (No
treatment and Drug); JF* < 0.05 versus Drug; fP < 0.05 versus No
treatment; aP = 0.065 versus No treatment; hP - 0.075 versus No
treatment.
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Figure 21, continued. Quantitative assessment of IL4, IL13, MCP-1,
VEGF, and TGF-pl in RM-9 tumors. Treatment was given as indicated.
Each bar represents the mean ± SEM for n = 8-10 mice/group. **/> <
0.05 versus Radiation; #P < 0.05 versus non-irradiated tumor-bearing
groups (No treatment and Drug); %P < 0.05 versus Drug; fF* < 0.05
versus No treatment; aP = 0.065 versus No treatment; hP = 0.075 versus
No treatment.
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Table 5. Proportion of Cytokine Levels Compared to Group with No Tumor or Nontreated Tumor-bearing Group. Three cytokines (IL7, IL12, and IL15) in spleen
supernatants were below the level of detection; levels of four additional cytokines were
not affected by tumor presence or treatment (ILlp, IL9, IL17, and RANTES). *Only a
trend was noted for differences in tumor TGF-p 1.
Tumor-bearing groups
Location and
cytokine

No tumor
group

No
treatment

Drug

Radiation
0.41
0.39

Drug +
Radiation

Spleen supernatant
G-CSF
GM-CSF

LOO
1.00

0.35

0.27

0.22

0.25

IFN-y

1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

0.46
1.80
1.83
1.27
1.83
0.59
0.51
0.76
4.18
0.28
0.25

0.30

1.00
1.00
1.00
1.00
1.00

0.51
0.32

0.13

0.45
1.51
4.15
2.53
1.73
1.83
0.60
0.56
5.69
0.21

0.20

0.37

0.34

1.07
0.60

0.83
0.58

1.02
0.79

0.70

1.37
1.94
5.36

1.43
1.37
4.15

0.75

0.94

0.77

3.62

1.15
5.30

1.00

0.79

1.17

0.85

IL13
MCP-1

1.00
1.00

0.59
0.94

0.89
1.59

0.95
1.58

TGF-P 1*

1.00

0.54

0.56

0.91

VEGF

1.00

0.45

2.25

0.67

ILlp
IL4
IL5
IL6
IL13
IL10
IP-10
MCP-1
MIP-la
mKC
TGF-bl
TNF-a
Plasma
IL4
IL13
MCP-1
Tumor
IL4

1.75
1.71
1.87
1.73
1.02
0.62
0.72
4.23
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0.36
2.01
2.64
2.37

2.06
0.70

0.62
0.56
7.36
0.14

0.88

Table 6. Cytokines in Spleen Supernatants That Were Unaffected by Tumor Presence and
Treatment. Results represent means and SEM {n = 8-10 mice/group, for the four
cytokines that were not significantly affected by either tumor presence or treatment
(ILla, IL9, IL17, and RANTES). Values are in pg/ml.
Tumor-bearing groups
No tumor
group

No
treatment

Drug

Radiation

Drug +
Radiation

ILla

138 ±60

78 ±4

64 ±5

87± 14

110± 12

IL9

63± 18

54± 15

51 ±8

54 ±8

63 ±20

IL17

1302 ±324

785 ± 93

895 ± 65

919 ±75

873±108

140 ± 12

144 ±20

131 ±13

115 ± 6

133 ± 16

RANTES
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Discussion
We have previously reported that treatment with metalloporphyrin antioxidants
does not adversely affect prostate tumor response to radiation and may even provide anti
tumor effects (Makinde, et ah, 2009). The data with MnTE-2-PyP showed no significant
differences in tumor volume or length of time before maximum allowed tumor size was
achieved in the mice receiving radiation alone or drug plus radiation {24). However, we
found that treatment with MnTE-2-PyP alone significantly elevated CD4+ T helper (Th),
CD8+ T cytotoxic (Tc), and NK1.1+ NK cells in the spleen, CD19+ B cells in the blood
and spleen, and the capacity of splenocytes to produce IL2 (Makinde, et ah, 2009). More
specifically, tumor-bearing mice receiving only MnTE-2-PyP had the highest CD4+ Th
cell count (4.97 ± 0.45 x 106/mm3) in the spleen at 12 days after RM-9 cell injection and
differed significantly from all other groups {P < 0.05). The mean values for CD4+ T cells
in the other tumor-bearing groups were: 3.92 x 106/mm3 (No treatment), 2.09 x 106/mm3
(Radiation), and 1.17 x 106/mm3 (Drug + Radiation); for mice without tumor, the mean
was 2.75 x 10 /mm . The CDS Tc cells followed a similar pattern, with the Drug only
group having the highest mean value of 2.99 ± 0.33 x 106/mm3. Additional data for
leukocyte, erythrocyte, and thrombocyte populations were also reported {24).
These findings supported the conclusion that the drug has a positive effect on
immune responsiveness and thus may also have potential to slow tumor progression. The
specific mechanisms underlying these observations have, however, not been elucidated.
Our main goal in the present study was to quantify cytokines secreted after T cell
activation and to assess the levels of selected cytokines in plasma and tumors. Mice with
and without the RM-9 prostate tumor were utilized to further explore the relationship
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between tumor irradiation, drug treatment and its interaction with the immune system.
More specifically, cytokines that have potential to modulate immune responses, as well
as affect treatment outcome, were investigated. Day 5 post-irradiation (i.e., day 12 after
RM-9 tumor cell implantation) was selected for the analyses reported here. Although
radiation effects can occur in less than 5 days post-exposure, some can be persistent and
result in late/chronic toxicities. Furthermore, this time point was selected because the
mice had received 12 daily injections of MnTE-2-PyP (thus increasing the probability
that drug effects would be manifested) and because it was within the time interval during
which we found an enhanced anti-tumor effect when a similar metalloporphyrin
antioxidant was used together with radiation in the RM-9 tumor model (25).
The results for spleen cell supernatants showed a significant radiation-induced
increase in IL4, IL5, and IL13 (Figurel? 1), all of which can be secreted by Th2 cells.
While treatment with MnTE-2-PyP alone did not have an effect, addition of the drug to
radiation significantly decreased the radiation-induced elevation of IL4 and IL13 (P<
0.05). Both cytokines have similar biological activities and are secreted by theTh2 subset
that inhibits cell-mediated immunity (Terabe, Park, & Berzofsky, 2004; Zurawski & de
Vries, 1994). They are associated with a host of immune processes ranging from
suppressing apoptosis (Conticello, et ah, 2004; Li, et al., 2008; Manna & Aggarwal,
1998) and down-regulating pro-inflammatory cytokines to increasing the production of
chemokines (Pope, et al., 2001) and anti-inflammatory and adhesion molecules (Terabe,
et al., 2004). Inhibition of IL4 and IL13 in recent years has been a focus in anti-tumor
immunotherapy (Becker, 2006; Conticello, et al., 2004; Li, et al., 2008; Todaro, et al.,
2008). Thus, the decrease in IL4 and IL13 in spleen supernatants that resulted when
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MnTE-2-PyP was combined with radiation suggests that the previously published data
showing an anti-tumor effect of metalloporphyrin antioxidants (Makinde, et ah, 2009;
Moeller, et ah, 2005b) may be at least partly related to decreased production of these two
cytokines and/or Th2 cell responsiveness in general. Additionally, there is mounting
evidence that an increase in Th2 type response can lead to radiation-induced fibrosis, a
serious consequence of radiotherapy seen in some patients (Jakubzick, Kunkel, Puri, &
Hogaboam, 2004; Westermann, Schobl, Rieber, & Frank, 1999). These latter findings
suggest that MnTE-2-PyP may minimize risk for normal tissue toxicity. Although the
Th2 subset is well-established as a source of IL4 and IL13, the precise origin of these
cytokines in the present study remains to be determined, since NKT cells can also secrete
them (Akbari, et ah, 2003) and it is currently not known whether the drug affects this cell
population.
Plasma concentrations of IL4 and IL13 exhibited different patterns; tumor- and
treatment related effects on IL13 were much more striking than on IL4 (Figures
20A&B). The significant increase in IL13 resulting from tumor presence (compared to
No Tumor control) is consistent with the immunosuppressive nature of tumors. Evidence
indicates that IL13 is a major inhibitor of tumor immunosurveillance mediated by NKT
cells (30). In contrast to results seen in spleen supernatants, MnTE-2-PyP and radiation
when used either singly or in combination significantly decreased IL13 concentration in
the plasma. These data suggest that both treatment modalities may diminish systemic
immunosuppression resulting from tumor-associated elevation in IL13. The significantly
decreased IL13 in RM-9 tumors from mice treated only with the drug (Figure 2IB)
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further support the possibility that MnTE-2-PyP may have an “anti-immunosuppressive”
effect.
The results showed reduction in splenocyte capacity to produce TGF-pl when the
drug was added to radiation, suggesting that the combination treatment may be beneficial
(Fig 17D). As a cytokine with multiple functions, TGF-pl plays important and
sometimes contrasting roles in cancer formation and progression. In early stages of
carcinogenesis, it serves as a tumor suppressor, while in later stages it functions as an
immunosuppressive cytokine with potential to promote tumor growth, invasion,
angiogenesis, and metastasis (Abate-Shen & Shen, 2000; Bierie & Moses, 2006; Rich, et
ah, 2001). Although most immune cells can secrete TGF-pl (Letterio & Roberts, 1998),
it would be particularly interesting to investigate the CD4+/CD25+ T regulatory (Treg)
cells in this regard, as they are known to secrete the factor (Teicher, 2007) and have been
widely implicated in immune evasion of tumors (Fujita, et ah, 2009; Wan & Flavell,
2007a, 2007b; Wrzesinski, Wan, & Flavell, 2007). The lack of significant differences
among groups in tumor TGF-pl maybe due to high TGF-pi expression by this murine
prostate cancer model. RM-9 cells have been reported to secrete TGF-pl (Nasu, et al.,
2001); additionally, we have also noted high production in vitro (unpublished data).
Nonetheless, the findings warrant further investigation, especially since TGF-pl is
known to be a major promoter of radiation-induced fibrosis (50).
The increase in ILlp, IL6, and MCP-1 in spleen supernatants resulting from
untreated RM-9 tumor presence correlates with the fact that inflammation has been
widely associated with cancer progression (Allavena, Garlanda, Borrello, Sica, &
Mantovani, 2008; Lee & Stupans, 2002). Production of TNF-a, a cytokine also frequently
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thought of as pro-inflammatory, was significantly decreased in these same mice.
However, treatment with MnTE-2-PyP together with radiation significantly enhanced the
level of this factor compared to the non-treated tumor-bearing controls. As a
multifunctional cytokine, TNF-a is involved in the regulation of various processes
including the induction of apoptosis, indicating a possible increase in tumor cell
apoptosis in the groups receiving the combination treatment. The concurrent
enhancement of MCP-1 production in the group receiving both treatment modalities, as
well as the trend for a higher level of MCP-1 in the blood circulation compared to
radiation alone (Figure 20C), suggests that recruitment of monocytes/macrophages to
apoptotic tumor cells maybe facilitated (Manome, et ah, 1995). Macrophages are a
prominent part of effective immune responses and exhibit various functions, depending
on the physiological or pathological milieu into which they are recruited. They are
capable of lysing cancer cells, presenting tumor-associated antigens, and stimulating anti
tumor activities of T and NK cells (Lamagna, Aurrand-Lions, & Imhof, 2006; Lewis &
Pollard, 2006). Thus, increased ability to produce MCP-1 and TNF-a may facilitate
overall efficacy of malignant cell destruction by the immune system. Additionally,
keeping in line with previous reports (55), our data show a radiation-induced increase in
tumor MCP-1 (regardless of drug treatment), consequently supporting a possible increase
in macrophage migration into the tumor microenvironment.
Quantification of tumor VEGF demonstrated significant effects of MnTE-2-PyP
and radiation, both alone and in combination (Figure 2ID). More notable than the
significant radiation-induced elevation in tumor VEGF was the decrease observed when
the drug was combined with radiotherapy. This factor is a well-known and characterized
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pro-angiogenic cytokine and its increased expression has been associated with poor
prognosis in a variety of human cancers (Yamamoto, et ah, 1996). It plays a major role
in tumor growth/development, as it is necessary for recruitment of new blood vessels that
are required to supply oxygen and nutrients to the tumor cells. VEGF has also been
implicated in immunosuppression and anti-VEGF agents are currently of great interest in
cancer therapy (Frumento, Piazza, Di Carlo, & Ferrini, 2006). Overall, the decrease in
tumor VEGF resulting from MnTE-2-PyP treatment, either alone or in combination with
radiation, is intriguing and favors the possibility that the drug may have anti-tumor
efficacy.
The results showed that presence of the RM-9 tumor had a significant depressive
effect on splenocyte production of G-CSF, GM-CSF, IFN-y, IL10, IP-10, MIP-la, and
mKC regardless of treatment received. Although tumor-induced immunosuppression has
been well established over the years, very little information is available on cytokines
produced by bone marrow-derived populations in an immunocompetent animal model of
prostate cancer. The diminished ability of the immune system to recognize tumors may
be due to the down-regulation of tumor-associated antigens, impairment of antigen
presentation, and secretion of immunosuppressive cytokines (Croci, et al., 2007). Tumorderived factors frequently recruit myeloid cells with inhibitory properties (Kusmartsev &
Gabrilovich, 2002); the recruited cells often have markers associated with macrophages
and dendritic cells. In cancer patients and tumor-bearing mice, development of adaptive
immune responses mediated by T cells can be compromised by myeloid-derived
suppressors infiltrating lymphoid organs such as the spleen (Kusmartsev & Gabrilovich,
2006). These suppressor cells proliferate rapidly and produce high levels of ROS that
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prevent their differentiation into a mature phenotype capable of antigen presentation
(Corzo, et ah, 2009; Kusmartsev & Gabrilovich, 2006)., thereby suggesting that
administration of ROS scavengers, such as MnTE-2-PyP, could facilitate their maturation
and thus also enhance their ability to present tumor antigens to T cells. Indeed, reports
have indicated that treatment with antioxidants can diminish the evasion/suppression
mediated by tumor cells (Malmberg, 2004). In addition to enhanced TNF-a and MCP-1
in spleen supernatants discussed above, we have previously found that IL2 production
was significantly elevated by MnTE-2-PyP treatment (Makinde, et ah, 2009). IL2, a Thl
cell-derived cytokine is required for T cell activation and subsequent expression of
cytotoxic and helper functions of the Tc and Th subsets. The Thl cell response can
apparently be highly effective in tumor prevention and therapy (Becker, 2006). Ongoing
clinical trials involving IL2 and other Thl cell-derived cytokines emphasize the potential
usefulness of these factors in cancer immunotherapy (Brill, et ah, 2007; Croci, et ah,
2007).

In conclusion, presence of the RM-9 prostate tumor had profound effects on many
of the quantified cytokines; a depressive effect occurred more often than enhancement.
Treatment with MnTE-2-PyP and tumor-localized radiation also altered levels of certain
cytokines. Most importantly, administration of the drug decreased the radiation-induced
enhancement in levels of IL4, IL13, and TGF-pl in spleen supernatants and IL4 and
VEGF in tumors. Collectively, these cytokines can down-regulate anti-tumor immune
responses and facilitate radiation-induced normal tissue toxicities. However, it should be
pointed out that cytokine interactions are complex and cellular responses to these
molecules are dependent on factors such as cell type, state of the cell, and the receptors
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present on their membranes. It should also be noted that the results for cytokines in
spleen cell supernatants and in tumor homogenates were derived from mixtures of cells.
Nonetheless, the data demonstrate that the cytokine profile was significantly modified by
Mn-TE-2-PyP in the major organ that initiates an immune response against antigens
circulating in the blood, as well as in the tumor mass itself. Additional studies are needed
to determine whether the drug can enhance tumor immunogenicity, facilitate maturation
of myeloid-derived suppressor cells, and/or minimize risk for complications due to
radiation.
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CHAPTER FOUR
UNPUBLISHED RESULTS
Introduction
Published data with MnTE-2-PyP and other similar SOD mimetics have shown the
potential of antioxidants to have antitumor activity in addition to its radioprotective effect
on normal tissues (Moeller, et ah, 2005b). We believe the ability of these types of drugs
to function as anti-tumor agents could potentially enhance tumor sensitivity to radiation.
By scavenging for ROS, MnTE-2-PyP may hinder the capacity of PCa cells to exist and
survive in their current pro-oxidative neoplastic state.
Cells are constantly exposed to multiple opposing death and survival signals and
the dysregulation of this balance is often associated with cancer. Based on our previous
studies and current literature, we believe that HIF-loc and NF-kB play important roles in
response of prostate tumors to the cellular redox state. Both of these transcription factors
have been reported to be over-expressed in a variety of cancers and are associated with
carcinogenesis, cancer progression, metastasis, radioresistance in solid tumors and poor
prognosis (Galanis, et ah, 2008; Maxwell, 2005; Rankin & Giaccia, 2008).
NF-kB is an early responder to various stimuli ranging from cytokines to ROS;
radiation, as an inducer of ROS, is thus involved in regulation of cell survival and
proliferation, as well as immune and inflammatory responses. Furthermore, although the
majority of current information on HIF-la activation is from studies related to hypoxia,
recent reports show that ROS also induce stabilization of the a-subunit in normoxic
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conditions (Bacon & Harris, 2004; Galanis, et al., 2008; Ke & Costa, 2006). Some studies
have also demonstrated the role of NF-kB in HIF-loc activation in response to ROS
(Bonello, et al., 2007; Gorlach & Bonello, 2008; van Uden, et al., 2008). Its activation
leads to translocation from the cytoplasm into the nucleus where it modulates gene
expression.
We proposed that HIF-la and NF-kB may play important roles in the biological
impact of MnTE-2-PyP. We examined the effects of the drug on PCa cell lines and their
response in terms of cell survival, death, viability and promoter activity for these two
transcription factors. We also investigated expression of specific genes related to HIF-la
and NF-kB activity in RM-9 tumor response to MnTE-2-PyP and radiation.

Materials and Methods
Cell Cultures
RM-9 is a prostate cancer cell line that was originally derived from a ras + myc
transformed/wild-type TP53 primary prostate tumor induced in the Zipras/myc-9-infected
mouse prostate reconstitution (MPR) model using syngeneic C57BL/6 mice. This cell
line has been extensively evaluated for pathological and phenotypic characteristics and
was selected because of its close similarity to human prostate cancer (Thompson, et al.,
2000). The cells were cultured in Dulbecco’s Modified Eagle’s Medium (GIBCO,
Gaithersburg, MD, USA) completed with 10% bovine calf serum (BCS; Hyclone
Laboratories, Logan, UT, USA), 10 mM HEPES buffer, penicillin (100 lU/ml), and
streptomycin (10 mg/ml) at 37°C in a humidified atmosphere containing 5% CO2.
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The LNCaP cell line was derived from a metastatic lesion (in lymph node) of
human PCa. These cells have been reported to be androgen sensitive and to express PSA
at different concentrations (Webber, Bello, & Quader, 1997a, 1997b). It exists as the
currently most favored representative of human PCa that would be treated with radiation.
The cells were cultured in RPMI (Mediatech, Herndon, VA, USA) completed with 10%
BCS (Hyclone Laboratories), 10 mM HEPES buffer, penicillin (100 lU/ml), and
streptomycin (10 mg/ml) at 37°C in a humidified atmosphere containing 5% CO2.
PC-3 is a human cell line originally derived from advanced, androgen independent
PCa that had metastasized to bone (Webber, et al., 1997a, 1997b). The cells were
cultured in F-12 Kaighn’s medium (Mediatech) completed with 10% BCS (Hyclone
Laboratories), 10 mM HEPES buffer, penicillin (100 lU/ml), and streptomycin (10
mg/ml) at 37°C in a humidified atmosphere containing 5% CO2.
The DU-145 cell line was derived from a metastatic brain mass in a patient with
PCa; it is androgen independent (Webber, et al., 1997a, 1997b). The cells were cultured
in MEM medium (Mediatech) completed with 10% BCS (Hyclone Laboratories), 10 mM
HEPES buffer, penicillin (100 lU/ml), and streptomycin (10 mg/ml) at 37°C in a
humidified atmosphere containing 5% CO2.

Drug Treatment of Cells in Vitro
For all of the assays described below, MnTE-2-PyP was diluted in media
appropriate for each cell type and then added to the cells (0.1 ml/well) at 30 min prior to
irradiation. The amount of drug added to respective wells in replicates of four was as
follows: a) 0 pmol; b) 2 pmol; c) 5 pmol; d) 7 pmol; and e) 10 pmol.
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Irradiation of Cells in Vitro
Exposure to y-radiation was performed using a 60Cobalt (60Co) source from an
AECL Eldorado Model gamma (y) irradiation machine (Atomic Energy of Canada, Ltd.,
Commercial Products Division, Ottawa, Canada). To irradiate cells, a vertical beam
projected to a 30 x 30 cm field size was used to expose cells grown in the 96-well plates.
The plates were covered with a polystyrene sheet of 5 mm thickness for electron
equilibrium. Radiation was delivered to cells in different plates in a single fraction at a
dose rate of 1.6 Gy/min; total doses were 0, 2, 5 and 10 Gy.

Tritiated Thymidine (3H-Tdr) Incorporation Assay
Cells were harvested, washed, re-suspended and counted. Cell concentration was
adjusted to IxlO5 cells/ml. Aliquots (100 pi) of single celled suspensions were dispensed
into flat-bottom wells of 96-well plates and allowed to establish overnight. Thirty
minutes prior to irradiation, appropriate MnTE-2-PyP concentrations in replicates of four
or media was added to the wells; cells were irradiated approximately 24 h after plating.
Four hours prior to each time point of cell harvest, 3H-TdR (specific activity = 46
Ci/mmol; ICN Radiochemicals, Irvine, CA, USA) was added at 1 pCi/5 Opl/well. Cells
were harvested 24, 48 and 72 h after irradiation with 0.25% trypsin solution using a
Tomtec multiple-sample harvester (Hamden, CT, USA) onto a single filter paper
subdivided into 96 sections. Each filter paper was sealed in a sample plastic bag with 5
ml of beta scintillation fluid. The incorporation of radioactivity into cell DNA (counts
per minute; cpm) was then quantified in the Trilux 1450 MicroBeta liquid scintillation
counter (Wallac, Turku, Finland).
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Cellular Viability Assay
This test quantifies the number of viable cells based on the level of adenosine
triphosphate (ATP) present in cell cultures. Cells were harvested, washed, re-suspended
and counted. Cell concentration was adjusted to IxlO5 cells/ml. Aliquots (100 pi) of
single celled suspensions were plated in replicates of four into flat-bottom 96-well white
polystyrene opaque plates (Costar/Coming, Acton, MA, USA) and incubated overnight at
37°C. Thirty minutes prior to irradiation, appropriate MnTE-2-PyP concentrations or
media were added to each well; cells were irradiated approximately 24 h after plating.
After 6, 24, 48 h of incubation, cell viability was determined using Cell Titer-Glo
(Promega, Madison, WI, USA) according to the manufacturer's instructions. Assay
reagent (100 pi) was added to cells at room temperature, mixed and incubated for
approximately 30 min. Luminescent signal was read using a multimode plate reader
(Infinite M200, TEC AN, Durham, NC, USA).

Caspase Assay
Cells were harvested, washed, re-suspended and counted. Cell concentration was
adjusted to IxlO5 cells/ml. Aliquots (100 pi) of single celled suspensions were plated in
replicates of four into 96-well white polystyrene opaque plates (Costar/Coming) and
incubated overnight at 37°C. Thirty minutes prior to irradiation, appropriate MnTE-2PyP concentrations or media were added to each well; cells were irradiated
approximately 24 h after plating. After 6, 24, 48 h incubation, activity of capase-3 and
caspase-7 was determined using Caspase-Glo 3/7 assay (Promega) according to the
manufacturer's instructions. One-hundred microliters of assay reagent was added to cells
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at room temperature, mixed and incubated for approximately 30 min. Luminescence was
read using a multimode plate reader (Infinite M200, TECAN).

Plasmid Constructs and Transfections
Full-length NF-kB and pGL3-control luciferase vectors were purchased from
Panomics (Redwood City, CA). HIF-la promoter luciferase constructs were a gift from
Dr. Carine Michiels at the University of Namur in Belgium.
Prior to transfection experiments, cells were harvested, washed, re-suspended and
counted. RM-9 and LNCaP cell concentration was adjusted to 1x105 cells/ml. Aliquots
(100 pi) of single celled suspensions were dispensed into flat-bottom wells of 96-well
plates and allowed to establish overnight. The test vectors were co-transfected with
renilla vector pRL-SV40 (Promega) as the transfection efficiency control. Cells were
transfected using FuGENE 6 (Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s protocol using 2 pg of plasmid DNA at a transfection reagent/plasmid
DNA ratio of 3:1. Transient transfections were performed overnight (16-24 h) at 37°C in
5% CO2 and cells were allowed to recover in media.

Reporter Activity Assay
Thirty minutes prior to irradiation, appropriate MnTE-2-PyP concentrations or
media were added to each well; cells were irradiated approximately 24 h post
transfection. After a 6 and 24 h incubation, luciferase activity was quantified in a
multimode plate reader (Infinite M200, TECAN) using the dual luciferase-reporter
system (Promega) and as per the manufacturer’s instructions. The firefly luciferase
activity was normalized to the renilla luciferase activity to determine transfection
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efficiency. Results were expressed as mean fold change relative to that of mutant HIF-lot
promoter or empty PGL3 vector for NF-kB. The SEM were indicated by error bars.

Gene Expression in RM-9 Tumors
Tumor induction, MnTE-2-PyP administration and irradiation were performed as
described in Chapter 2. RM-9 prostate tumor cells were injected s.c. into male C57BL/6
mice. Intraperitoneal injections of MnTE-2-PyP were initiated 1 day after tumor
induction and administered at 6 mg/kg for a total of 12 days. A single fraction of 10 Gy
y-radiation was delivered to the site of the tumor on day 8. Animals (n= 4/group) were
grouped as follows: a) No Treatment, b) MnTE-2-PyP Only, c) Radiation Only, and d)
Combination: MnTE-2-PyP + Radiation. At the time of euthanasia, tumors were
harvested in an RNase-free manner, snap frozen in liquid nitrogen and stored at -80°C
until RNA isolation prior to microarray analysis. Analysis of gene expression was
performed by quantitative real-time reverse transcriptase polymerase chain reaction (RTPCR) using standard techniques; a brief description is presented here. The samples were
homogenized in 2 ml of Trizol and RNA extraction was done following the Trizol
protocol for RNA extraction (Invitrogen). RNA samples were run on a bioanalyzer
(Agilent Technologies, Santa Ana, CA, USA). RNA integrity was assessed by looking at
18 and 28s rRNA peaks and by the RIN (RNA integrity number). Spectrophotometric
measurement showed that all samples had 260/280 ratios above 2.0 and 260/230 ratios
above 1.7. An equal amount of RNA (5 mg) was taken for all samples and reverse
transcription was done using C-01 Reaction Ready™ First Strand cDNA Synthesis Kit
(SABiosciences, Frederick, MD, USA). PCR reactions were performed using the Mouse
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NF-kB Signaling Pathway Array (RT2 Profiler™ PCR array PAMM-025; SABioscences)
and the Mouse Hypoxia Signaling Pathway (RT2 Profiler™ PCR array PAMM-032;
SABioscences). Relative changes in gene expression were calculated using the AACt
(threshold cycle) method.

Statistical Analysis
The data analysis was performed using SPSS (SPSS Inc). Two or three-way
ANOVA was used to evaluate effect of treatments on cells cultured in vitro, with drug
dose, radiation dose and time as the independent variables. Fold-change in gene
expression compared to tumor samples from control mice (no drug and no radiation) was
evaluated using Student’s t test. Data are reported as mean ± standard error of the mean
(SEM). A p<0.05 indicated significance, whereas p<0.1 was selected to indicate a trend.

Results
Tritiated Thymidine (3H-Tdr) Incorporation Assay
Radiation significantly decreased 3H-TdR incorporation in LNCaP cells regardless
of treatment with MnTE-2-PyP (Figure 22). Additionally, the non-irradiated group
showed a significant dose-dependent response to drug with 10 pmol having the greatest
anti-proliferative effect. We report a significant interaction between radiation, drug
treatment and time post-irradiation. The non-irradiated PC-3 cells exhibited highly
significant decrease in H-TdR incorporation in an MnTE-2-PyP dose-dependent manner
at 24 h post-treatment (Figure 23). Radiation also had an inhibitory effect on DNA
synthesis in PC-3 cells at all time points). In RM-9 mouse prostate tumor cell response to
radiation over time, a significant interaction in H-TdR incorporation was observed
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regardless of drug treatment. An inhibitory effect of drug was observed at the higher
doses 24 h post-treatment (Figure 24). DU-145 human prostate cancer cells exhibited
similar response to radiation as the RM-9 cells (Figure 25).
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Figure 22. DNA synthesis in LNCaP cells. Results were expressed as mean counts per
minute, CPM ± SEM. The SEM are indicated by error bars. P < 0.05 indicates
significance as follows: aDrug effect; bRadiation effect; interaction between drug and
radiation; dtime effect; * Interaction between drug dose and incubation time post
treatment.
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Figure 23. DNA synthesis in PC-3 cells Results were expressed as mean counts per
minute, CPM ± SEM. The SEM are indicated by error bars. P < 0.05 indicates
significance as follows: aDrug effect; bRadiation effect; interaction between drug and
radiation; dtime effect; * Interaction between drug dose and incubation time post
treatment.
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Figure 24. DNA synthesis in RM-9 cells Results were expressed as mean counts per
minute, CPM ± SEM. The SEM are indicated by error bars. P < 0.05 indicates
significance as follows: aDrug effect; bRadiation effect; interaction between drug and
radiation; dtime effect; * Interaction between drug dose and incubation time post
treatment
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Figure 25. DNA synthesis in DU-145 cells. Results were expressed as mean counts per
minute, CPM ± SEM. The SEM are indicated by error bars. P < 0.05 indicates
significance as follows: aDrug effect; bRadiation effect; Tnteraction between drug and
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treatment.
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Cellular Viability Assay
Viability of LNCaP cells was significantly decreased with time post treatment in
non-irradiated control and also radiation-treated groups treated with MnTE-2-PyP.
Treatment with drug alone also significantly decreased cellular viability of LNCaP cells
at both 24 and 48 h post irradiation (Figure 26). RM-9 cell viability did not exhibit a
consistent response to either radiation or drug treatment (Figure 27).

Caspase Assay
Caspase activity significantly decreased over time in LNCaP cells; however,
significance versus the non-irradiated groups was only seen at 10 Gy, 24 h post-radiation
in LNCaP cells without drug treatment. Combination of drug with radiation did not have
any significant effect on caspase activity, decrease was also observed over time.
Radiation significantly increased caspase activity in RM-9 cells regardless of drug
treatment. Highest caspase activity observed 48 h post-radiation (Figures 28 and 29). A
significant interaction between radiation and time was observed (P < 0.05).
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Figure 26. Cellular viability in LNCaP cells. Results were expressed as
percent viability versus the non-treated control. The SEM are indicated by
error bars. P < 0.05 indicates significance as follows: aDrug effect;
bRadiation effect; clnteraction between drug and radiation; d time effect;
* Interaction between drug dose and incubation time post-treatment.
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Figure 27. Cellular viability in RM-9 cells. Results were expressed as
percent viability versus the non-treated control. The SEM are indicated by
error bars. P < 0.05 indicates significance as follows: aDrug effect;
bRadiation effect; cInteraetion between drug and radiation; d time effect;
* Interaction between drug dose and incubation time post-treatment.
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Figure 28. Caspase activation LNCaP cells. Results were expressed as
mean luminescence±SEM. The SEM are indicated by error bars. P < 0.05
indicates significance as follows: aDrug effect; bRadiation effect;
cInteraetion between drug and radiation; dtime effect; interaction between
drug dose and incubation time post-treatment.
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Figure 29. Caspase activation RM-9 cells. Results were expressed as mean
luminescence±SEM. The SEM are indicated by error bars. P < 0.05
indicates significance as follows: aDrug effect; bRadiation effect;
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Reporter Activity Assay
Treatment with drug and/or radiation did not have a significant effect on NF-kB
promoter activity in LNCaP cells (Figure 30). In contrast, a 2-fold increase in NF-kB
promoter activity was observed 24 h post-radiation in comparison to 6 h, regardless of
drug treatment in RM-9 cells (Figure 31). We also observed an increase in HIF-la
promoter activity over time in the non-irradiated MnTE-2-PyP-treated LNCaP cells.
Irradiated LNCaP cells without drug treatment exhibited a decrease in HIF-la promoter
activity over time, while HIF-la promoter activity in MnTE-2-PyP treated cells was not
affected over time. At 6 h after treatment, we did however observe an almost 3-fold
decrease in LNCaP cells treated with both drug and radiation (Figure 30). At this same
early time point of 6 h, HIF-la promoter activity was decreased 4-fold in non-irradiated
RM-9 cells treated with drug. No change in HIF-la promoter activity was observed
resulting from radiation after 6 or 24 h incubation regardless of drug treatment (Figure
31).
In this study, we examined the expression of NF-kB and hypoxia-regulated genes
in RM-9 mouse prostate tumors growing in vivo. Comparison in gene expression was
made after treatment with radiation alone and in combination with MnTE-2-PyP to
determine if the drug modified radiation effects. Gene expression in all groups treated
either with drug and/or radiation was also compared with the non-treated tumor control
group. The expression patterns of NF-kB and hypoxia- regulated genes that were
assessed included major elements involved in cell cycle control, DNA repair and
apoptosis.
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Figure 30. Promoter activity in LNCaP cells. Results were expressed as
mean fold change relative to that of mutant HIF-1 a promoter for
change in HIF-1 a promoter activity or empty PGL3 vector for change
in NF-kB promoter activity. Values represent mean fold change ±SEM.
The SEM are indicated by error bars. P < 0.05 indicates significance as
follows: aDrug effect; bRadiation effect; clnteraction between drug and
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time post-treatment.
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Figure 31. Promoter activity in RM-9 cells. Results were expressed as
mean fold change relative to that of mutant HIF-1 a promoter for
change in HIF-1 a promoter activity or empty PGL3 vector for change
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Gene Expression in RM-9 Tumors
Up-regulation of hypoxia-related genes Hk2, Peal5a, Gpi, Vegfa and Adm (1.34 to
4.09 fold, P < 0.05) was seen in the combination group versus the group that received
only radiation (Figure 32). Radiation led to the up-regulation of 9 hypoxia-related genes,
Adm, Epasl, Kit, Cygb, DapkS, Sard, Il6st, Agtpbpl, and Crebbp and down-regulation of
Snrp70, Sumo2, Drl, Eeflal, Cstb, Caspl, Angptld, Ilia and Npy (-4.15 to -1.23, P <
0.05) (Figure 33). Treatment with MnTE-2-PyP presented a down-regulation in hypoxiarelated genes Sord and Il6st (-1.67 to -1.40 fold, P < 0.05) (Figure 34). Combination of
drug and radiation resulted in up-regulation of hypoxia related genes Snrp70, Sumo2,
Ep300, Hk2, Eeflal, Idl, Cdc42, Cstb, Peal5a, Vegfa, Prkaal, Gpil, Ilia, Man2bl and
Npy (1.22 to 4.03 fold, P < 0.05) and a down-regulation of kit, Dctn2, Bhlhb2, Dapk3,
Cygb and Agpat2 (-2.37 to -1.35 fold, P < 0.05) (Figure 35).
NF-icB-regulated genes, Csf3 and Tnfrsfla were significantly up-regulated (1.29 to
3.53 fold, P < 0.05) while Mapk3 was down-regulated in the group that received
combination of drug+radiation versus the radiation only group (Figure 36). Radiation
only treatment, led to down-regulation of Aktl and Mapk3 (-1.38 to -1.21 fold, P < 0.05)
and up-regulation of Nfkbl, AtffGjal, Eif2ak2, Rela, Caspl, Irak2, Ltbr, Tnfsfl4, Relb,
Tnfrsfla, Traf3, Ccl2, Tlrl, Ripk2, TnfrsflOb, Nodi, Tlr3, Iraki, Cd40, Nfkbia, Zap70,
Fasl and Q/2(1.20 to 3.74 fold, P < 0.05) (Figure 37). Addition of MnTE-2-PyP to
radiation up-regulated 23 genes NF-kB regulated genes including Nfkbl, Atf Tollip,
Rela, Relb,TnfrsflOb, Tnfsfl4, Traf3, Lbtr, Chuk, Tlr3, Irak2, Tnfrsfla, Ripk2, Cd40, Tlr1, Nodi, Tlr4, Fasl, Iraki, Csf2, Nfkbia and BcllO (1.21 to 3.27 fold, P < 0.05) while 4
NF-kB regulated gonesAktl, Mapk3, Elkl and Tbkl (-1.56 to -1.27, P < 0.05) were
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down-regulated (Figure 39). TnfsflO, C3 Statl, Rel, and MapkS were up-regulated (1.18
to 1.92, P < 0.05) while Gjal, TrafS, Jun and 1110 were down-regulated (-3.85 to -1.11, P
< 0.05) in group that received MnTE-2-PyP treatment only (Figure 40).
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Table 7. Differentially Expressed Hypoxia-related Genes in RM-9. Tumors treated with
Combination of MnTE-2-PyP and Radiation vs. Radiation Only. Results are reported as
mean of fold change (n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Up-regulated genes
Pdia2
Protein disulfide isomerase associated 2
Solute carrier family 2 (facilitated glucose transporter),
Slc2a4
member 4
Adm
Adrenomedullin
Mylpf
Myosin light chain, phosphorylatable, fast skeletal muscle
Insulin-like growth factor 2
Igf2
Vegfa
Vascular endothelial growth factor A
Gpil
Glucose phosphate isomerase 1
Peal5a
Phosphoprotein enriched in astrocytes 15 A
Hk2
Hexokinase 2
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Fold
Change
5.03
4.13
4.09
3.75
2.05
1.58
1.50
1.37
1.34

Table 8. Differentially Expressed Hypoxia-related Genes in RM-9 Tumors treated with
Combination of MnTE-2-PyP and Radiation vs. the Non-Treated Group. Results are
reported as mean of fold change (n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Up-regulated genes
Pdia2
Protein disulfide isomerase associated 2
Npy
Neuropeptide Y
Man2bl
Mannosidase 2, alpha B1
Ilia
Interleukin 1 alpha
Gpil
Glucose phosphate isomerase 1
Prkaal
Protein kinase, AMP-activated, alpha 1 catalytic subunit
Vegfa
Vascular endothelial growth factor A
Peal5a
Phosphoprotein enriched in astrocytes 15 A
Cstb
Cystatin B
Cdc42
Cell division cycle 42 homolog (S. cerevisiae)
Idl
Inhibitor of DNA binding 1
Eeflal
Eukaryotic translation elongation factor 1 alpha 1
Gusb
Glucuronidase, beta
Ep300
El A binding protein p300
Sumo2
SMT3 suppressor of mif two 3 homolog 2 (yeast)
Snrp70
U1 small nuclear ribonucleoprotein polypeptide A
Down-regulated genes
Agpat2
1-acylglycerol-3-phosphate O-acyltransferase 2
Gapdh
Glyceraldehyde-3 -phosphate dehydrogenase
Cygb
Cytoglobin
Dapk3
Death-associated kinase 3
Bhlhb2
Basic helix-loop-helix domain containing, class B2
Dctn2
Dynactin 2
Mt3
Metallothionein 3
Kit
Kit oncogene
Carl
Carbonic anhydrase 1
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Fold
Change
5.00
4.03

1.99
1.92
1.83
1.75
1.75
1.62
1.51
1.50
1.39
1.39
1.37
1.28
1.23
1.22
1.35
1.59
1.67
1.84
1.99
2.00

2.16
2.37
3.22

Table 9. Differentially Expressed Hypoxia-related Genes in RM-9 Tumors treated with
Radiation Only vs. the Non-Treated Group. Results are reported as mean of fold change
(n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Up-regulated genes
Npy
Neuropeptide Y
Ilia
Interleukin 1 alpha
Angptl4 Angiopoietin-like 4
Caspl
Caspase 1
Cstb
Cystatin B
Eeflal
Eukaryotic translation elongation factor 1 alpha 1
Drl
Down-regulator of transcription 1
Gush
Glucuronidase, beta
Hprtl
Hypoxanthine guanine phosphoribosyl transferase 1
Sumo2
SMT3 suppressor of mif two 3 homolog 2 (yeast)
SnrpTO
U1 small nuclear ribonucleoprotein polypeptide A
Down-regulated genes
Crebbp
CREB binding protein
Agtpbpl ATP/GTP binding protein 1
I16st
Interleukin 6 signal transducer
Sord
Sorbitol dehydrogenase
Gapdh
Glyceraldehyde-3 -phosphate dehydrogenase
Dapk3
Death-associated kinase 3
Cytoglobin
Cygb
Kit
Kit oncogene
Epasl
Endothelial PAS domain protein 1
Nos2
Nitric oxide synthase 2, inducible
Insulin-like growth factor 2
Igf2
Ppara
Peroxisome proliferator activated receptor alpha
Carl
Carbonic anhydrase 1
Mt3
Metallothionein 3
Adm
Adrenomedullin
Solute carrier family 2 (facilitated glucose transporter), member
Slc2a4
4

Mylpf

Myosin light chain, phosphorylatable, fast skeletal muscle
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Fold
Change
2.63
1.98
1.93
1.61
1.51
1.36
1.33
1.28

1.26
1.20
1.13
1.23
1.23
1.24

1.35
1.45
1.52
1.55
1.70

1.87
2.34

2.39
2.92
3.30
3.41

4.15
6.59
7.38

Table 10. Differentially Expressed Hypoxia-related Genes in RM-9 Tumors treated with
MnTE-2-PyP Only vs. the Non-Treated Group. Results are reported as mean of fold
change (n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Down-regulated genes
I16st
Interleukin 6 signal transducer
Sord
Sorbitol dehydrogenase
Ucp2
Uncoupling protein 2 (mitochondrial, proton carrier)
Mt3
Metallothionein 3
Carl
Carbonic anhydrase 1
Insulin-like growth factor 2
Igf2
Solute carrier family 2 (facilitated glucose transporter),
Slc2a4
member 4
Mylpf
Myosin light chain, phosphorylatable, fast skeletal muscle
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Fold
Change
1.40
1.67
2.21
2.38
3.02

4.12
7.67
13.74

Table 11. Differentially Expressed NF- KB-related Genes in RM-9 Tumors treated with
Combination of MnTE-2-PyP and Radiation vs. Radiation Only. Results are reported as
mean of fold change (n=4). A change was deemed significant when P < 0.05.
Gene
Symbol

Gene Name

Up-regulated genes
Csf3
Colony stimulating factor 3 (granulocyte)
Tnffsfl a
Tumor necrosis factor receptor superfamily, member 1 a
Down-regulated genes
Mapk3
Mitogen-activated protein kinase 3
Nlrpl2
NLR family, pyrin domain containing 12
Zap70
Zeta-chain (TCR) associated protein kinase
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Fol
d
Change
3.53

1.29
1.27
2.18
3.11

Table 12. Differentially Expressed NF-KB-related Genes in RM-9 Tumors treated with
Combination of MnTE-2-PyP and Radiation vs. the Non-treated Group. Results are
reported as mean of fold change (n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Up-regulated genes
Nuclear factor of kappa light chain gene enhancer in B-cells 1,
Nfkbl
pl05
Atfl
Activating transcription factor 1
Tollip
Toll interacting protein
Rela
V-rel reticuloendotheliosis viral oncogene homolog A (avian)
Relb
Avian reticuloendotheliosis viral (v-rel) oncogene related B
Tnfrsfl Ob Tumor necrosis factor receptor superfamily, member 1 Ob
Tnfsfl4
Tumor necrosis factor (ligand) superfamily, member 14
Gusb
Glucuronidase, beta
Traf3
Tnf receptor-associated factor 3
Ltbr
Lymphotoxin B receptor
Chuk
Conserved helix-loop-helix ubiquitous kinase
Toll-like receptor 3
Tlr3
Irak2
Interleukin-1 receptor-associated kinase 2
Tnfrsfl a
Tumor necrosis factor (ligand) superfamily, member 1 a
Ripk2
Receptor (TNFRSF)-interacting serine-threonine kinase 2
Interferon gamma
Ifng
Cd40
CD40 antigen
Tlrl
Toll-like receptor 1
Tnf
Tumor necrosis factor (TNF superfamily, member 2)
Nodi
Nucleotide-binding oligomerization domain containing 1
Tlr4
Toll-like receptor 4
Colony stimulating factor 3 (granulocyte)
Csf3
Fasl
Fas ligand (TNF superfamily, member 6)
Iraki
Interleukin-1 receptor-associated kinase 1
Csf2
Colony stimulating factor 2 (granulocyte-macrophage)
Nuclear factor of kappa light chain gene enhancer in B-cells
Nfkbia
inhibitor, alpha
B-cell leukemia/lymphoma 10
Bel 10
Down-regulated genes
Gapdh
Glyceraldehyde-3 -phosphate dehydrogenase
Aktl
Thymoma viral proto-oncogene 1
Mapk3
Mitogen-activated protein kinase 3
Elkl
ELK1, member of ETS oncogene family
TANK-binding kinase 1
Tbkl
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Fold
Change

1.21
1.27
1.31
1.40
1.63
1.63
1.65
1.65
1.67
1.73
1.75
1.87
1.95
2.02

2.06
2.20
2.23

2.28
2.32

2.51
2.60
2.63
2.68
2.72
3.07

3.21
3.27

1.57
1.56
1.54
1.53
1.27

Table 13. Differentially Expressed NF-KB-related Genes in RM-9 Tumors treated with
Radiation Only vs. the Non-treated Group. Results are reported as mean of fold change
(n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Up-regulated genes
Csf2
Colony stimulating factor 2 (granulocyte-macrophage)
Fasl
Fas ligand (TNF superfamily, member 6)
Zap70
Zeta-chain (TCR) associated protein kinase
Nuclear factor of kappa light chain gene enhancer in B-cells
Nfkbia
inhibitor, alpha
Cd40
CD40 antigen
Iraki
Interleukin-1 receptor-associated kinase 1
Tlr3
Toll-like receptor 3
Tnf
Tumor necrosis factor (ligand) superfamily, member
Nlrpl2
NLR family, pyrin domain containing 12
Nodi
Nucleotide-binding oligomerization domain containing 1
TnffsflOb Tumor necrosis factor receptor superfamily, lObmember
Tlr4
Toll-like receptor 4
BcllO
B-cell leukemia/lymphoma 10
Ilia
Interleukin 1 alpha
Ripk2
Receptor (TNFRSF)-interacting serine-threonine kinase 2
Tlrl
Toll-like receptor 1
Ccl2
Chemokine (C-C motif) ligand 2
Traf3
Tnf receptor-associated factor 3
Tnffsfl a
Tumor necrosis factor receptor superfamily, lamember
Avian reticuloendotheliosis viral (v-rel) oncogene related B
Relb
oncogene related B
Tnfsfl4
Tumor necrosis factor (ligand) superfamily, 14member
Glucuronidase, beta
Gusb
Ltbr
Lymphotoxin B receptor
Irak2
Interleukin-1 receptor-associated kinase 2
Caspl
Caspase 1
Rela
V-rel reticuloendotheliosis viral oncogene homolog A (avian)
Eif2ak2
Eukaryotic translation initiation factor 2-alpha kinase 2
Gjal
Gap junction protein, alpha 1
Tnfaip3
Tumor necrosis factor, alpha-induced protein 3
Atfl
Activating transcription factor 1
Nuclear factor of kappa light chain gene enhancer in B-cells 1,
Nfkbl
pl05
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Fold
Change
3.74
3.07

2.78
2.73

2.67
2.66
2.27
2.20
2.20
2.07
2.07
2.07

2.06
2.02

1.94
1.90
1.70
1.59
1.57
1.55
1.54
1.54
1.53
1.45
1.40
1.32
1.28
1.28
1.26
1.24
1.20

Table 13, continued. Differentially Expressed NF-KB-related Genes in RM-9 Tumors
treated with Radiation Only vs. the Non-treated Group. Results are reported as mean of
fold change (n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Down-regulated genes
Mapk3
Mitogen-activated protein kinase 3
Aktl
Thymoma viral proto-oncogene 1
Gapdh
Glyceraldehyde-3 -phosphate dehydrogenase
C3
Complement component 3
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Fold
Change
1.21
1.38
1.38
2.09

Table 14. Differentially Expressed NF-KB-related Genes in RM-9 Tumors treated with
MnTE-2-PyP Only vs. the Non-Treated Group. Results are reported as mean of fold
change (n=4). A change was deemed significant when P < 0.05.
Gene
Gene Name
Symbol
Up-regulated genes
1110
Interleukin 10
Jun
Jun oncogene
Traf3
Tnf receptor-associated factor 3
Gjal
Gap junction protein, alpha 1
Down-regulated genes
Mapk3
Mitogen-activated protein kinase 3
Rel
Reticuloendotheliosis oncogene
Statl
Signal transducer and activator of transcription 1
C3
Complement component 3
Ifng
Interferon gamma
Tnfsfl 0
Tumor necrosis factor (ligand) superfamily, 10 member
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Fold
Change
1.92
1.44
1.24
1.18
1.11
1.50
1.89
2.63
3.72

3.85

Effect of MuTE-2-PyP on hypoxia-regulated
gene ext»i'ession in radiation-treated tumors
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Figure 32. Effect of MnTE-2-PyP on hypoxia-regulated gene expression in
radiation-treated tumors. Fold-change in MnTE-2-PyP only group versus
radiation only group. Results are reported as mean of fold change (n=4). A
change was deemed significant when P < 0.05 and reported in above
figure.
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Figure 33. Hypoxia-related gene expression in tumors treated with
radiation. Fold-change in radiation only group versus non-treated control
group. Results are reported as mean of fold change (n=4). A change was
deemed significant when P < 0.05 and reported in above figure.
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Figure 34. Hypoxia-related gene expression in tumors treated with MnTE2-PyP. Fold-change in MnTE-2-PyP only group versus non-treated control
group. Results are reported as mean of fold change (n=4). A change was
deemed significant when P < 0.05 and reported in above figure.
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Figure 35. Flypoxia-related gene expression in tumors treated with MnTE2-PyP+radiation..Fold-change in MnTE-2-PyP + radiation only group
versus non-treated control group. Results are reported as mean of fold
change (n=4). A change was deemed significant when P < 0.05 and
reported in above figure.

144

Figure 36. Effect of MnTE-2-PyP on NF-kB regulated gene expression in
radiation-treated tumors. Fold-change in MnTE-2-PyP + radiation only
group versus radiation only group. Results are reported as mean of fold
change (n=4). A change was deemed significant when P < 0.05 and
reported in above figure.
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Figure 37. NF-KB-related gene expression in tumors treated with radiation.
Fold-change in radiation only group versus non-treated control group.
Results are reported as mean of fold change (n=4). A change was deemed
significant when P < 0.05 and reported in above figure.
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Figure 37,continued. NF-KB-related gene expression in tumors treated with
radiation. Fold-change in radiation only group versus non-treated control
group. Results are reported as mean of fold change (n=4). A change was
deemed significant when P < 0.05 and reported in above figure.
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Figure 38. NF-icB-related gene expression in tumors treated with MnTE-2PyP+Radiation.Fold-change in MnTE-2-PyP + radiation only group versus
non-treated control group. Results are reported as mean of fold change
(n=4). A change was deemed significant when P < 0.05 and reported in
above figure.
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Figure 39. NF-KB-related gene expression in tumors treated with MnTE-2PyP+Radiation. Fold-change in MnTE-2-PyP + radiation only group
versus non-treated control group. Results are reported as mean of fold
change (n=4). A change was deemed significant when P < 0.05 and
reported in above figure.
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Figure 40. NF-icB-related gene expression in tumors treated with
MnTE-2-PyP only. Fold-change in MnTE-2-PyP only group versus
non-treated control group. Results are reported as mean of fold change
(n=4). A change was deemed significant when P < 0.05 and reported in
above figure.

150

Discussion
The maintenance of genomic integrity is very important for cellular proliferation
and survival. Proliferating cells synthesize new DNA and incorporate thymidine and
other bases in the process; in the presence of 3H-TdR, the DNA becomes radioactively
labeled. The synthesized DNA is quantified based on the amount of labeled thymidine
present in harvested cells. Inhibition of replicative DNA synthesis by ionizing radiation is
well documented due to an active, signal-mediated response termed the "S-phase
checkpoint (Falck, Petrini, Williams, Lukas, & Bartek, 2002; Kim, Xu, & Kastan, 2002;
Wu, et ah, 1999). The S-phase checkpoint is responsible for monitoring cell cycle
progression and decreases the rate of DNA synthesis (or stops it completely) following
DNA damage so that repair can take place. As expected, our results showed that radiation
significantly decreased DNA synthesis in the DU-145, PC-3, RM-9 and LNCaP cells.
Additionally, we observed that treatment with MnTE-2-PyP lead to a decrease in
thymidine incorporation in LNCaP cells which is indicative of decreased DNA synthesis,
thus suggesting that the drug had a negative effect on cell cycle progression. This drug
effect was, however, not observed in the other three cell lines. It seems possible that
because the mouse RM-9, human DU-145 and human PC-3 cell lines are more resistant
to the drug due to the fact that they represent the more advanced stages of prostate cancer
in which the malignant cells are more likely to continue proliferating even when
inhibitory signals are present.
Furthermore, assessment of cellular viability in LNCaP cells showed decreased
percent viability both in irradiated and non-irradiated cells treated with MnTE-2-PyP.
This latter finding also supports the possibility that the drug has an anti-proliferative
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effect on relatively low grade prostate cancer that is most likely to be treated with
radiation.
Although an early increase in cellular viability was observed in MnTE-2-PyPtreated RM-9 cells, results from our cell death analysis (apoptosis) showed that caspase
activation peaked at 48 h in RM-9 cells post-treatment, regardless of treatment. This
indicates that radiation-induced death of this relatively aggressive cell line was not
subdued by direct interaction with the drug.
Based on evaluation of pro-apoptotic mitochondrial enzymes, LNCaP cells
showed the greatest caspase 3/7 activity at 6 h post-irradiation reinforcing the
radio sensitivity of LNCaP cells. This early caspase activity might be at least partly
responsible for the decreased viability and low DNA synthesis observed at later timepoints in LNCaP cells. Since a similar radiation effect on caspase 3/7 activity did not
occur in RM-9 cells, the data support the conclusion that these cells are more
radioresistant compared to LNCaP.
Overall, our assessment of promoter activity of NF-kB and HIF-la in vitro did not
provide a clear pattern for MnTE-2-PyP-induced changes in cell response to radiation.
However, analysis of HIF-la promoter activity suggested that HIF-la was constitutively
elevated in both RM-9 and LNCaP cells and that treatment with MnTE-2-PyP downregulated promoter activity. If this possibility is proven to be correct in future studies, it
would indicate that the drug modifies pathways involved in activation of HIF-la in PCa.
RM-9 is known to be generally more resistant to radiation (Wang, et al., 2006), as it
represents PCa in more advanced stages. Current studies have implicated NF-kB activity
in radio-resistance of PCa. The radiation-induced increase in NF-kB promoter activity
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seen in the present study may explain the effect we see in regards to cell viability and
DNA synthesis.
Although, our results do not show consistent effects of treatment on response to
NF-kB and HIF-la promoter activity, we have been able to demonstrate that treatment
with the drug alters promoter activity of these two transcription factors that regulate the
expression of numerous genes. In order to gain a better understanding of the role of NFkB,

HIF-la and pathways responsible for the effect of MnTE-2-PyP on prostate cancer

and its response to radiation, further studies are required. Mechanisms by which NF-kB
potentiates the radiation response is not entirely understood and is probably influenced by
modification of multiple cellular pathways. Further investigation into the exact
interactions involved in modification of the cell’s response to radiation by MnTE-2-PyP
is needed.
Apart from driving angiogenesis, hypoxia has also been linked to changes in
cellular metabolism. Hk2, Peal5a and Gpi encode for proteins involved in cellular
metabolism, their up-regulation in the group that received combination treatment in
comparison to the irradiated group is indicative of altered metabolism. The hypoxiainduced angiogenic effect of Adm has been reported to be partially mediated by
enhancing Vegfa expression (Keleg, et al., 2007; Oehler, Norbury, Hague, Rees, &
Bicknell, 2001). The up-regulation of these two genes in the group receiving combination
of drug+radiation versus the irradiated group could be indicative of increased hypoxia
and could also be responsible for increased expression of genes involved in cellular
metabolism. The significant up-regulation oiEpas, a HIF-la associated gene that
encodes the HIF-2a protein (Ji, et al., 2003; Peng, Zhang, Drysdale, & Fong, 2000), in
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the group that was treated with radiation only was not evident in the group that received
both drug and radiation. This is consistent with the anti-angiogenic properties associated
with metalloporphyrin antioxidants because radiation results in a hypoxic environment
that leads to activation of genes needed for new blood vessel formation. Furthermore,
since HIF-2a is strongly associated with aggressive tumor phenotypes(Qing & Simon,
2009), the lack of up-regulation of the Epas gene when Mn-TE-PyP was used together
with tumor irradiation suggests that the drug may decrease risk for metastasis.
Additionally, the down-regulation of Caspl in the radiation only group suggests a
decrease in pro-apoptotic gene expression (Su, et al., 2009). Inhibition of apoptosis has
been implicated in radiation response under hypoxic conditions. Other genes that were
significantly down-regulated resulting from radiation treatment include Drl (Denko, et
al., 2003; Kim, Na, Hampsey, & Reinberg, 1997) which is known to inhibit transcription,
and Ilia which is expressed in response to cellular injury and is known to induce
apoptosis (Elkabets, et al., 2009; Song, et al., 2003). In combination with MnTE-2-PyP,
the radiation-induced down-regulation of these four genes was not observed. On the other
hand, combination of MnTE-2-PyP to radiation led to the up-regulation of Idl, Man2bl
and Ilia. The protein encoded by Idl inhibits DNA binding of helix-loop-helix proteins,
such as HIF-la, which are associated with the control of malignant cell behavior in
several types of cancers (Yap, et al., 2008; Yu, Xu, Han, & Zhou, 2009). Expression of
Man2bl is involved in glycoprotein metabolism via enzymatic action of the mannosidase
derived from this gene (http://0-www.ncbi.nlm.nih.gov) suggesting an increase in
glycoproteins. The glycoproteins are essential for immune recognition, since they are
functional parts of MHC class I molecules (Kindt, et al., 2007). This is important because
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virtually all nucleated cells, including tumor cells, have MHC class I consisting of
glycoprotein chains on their surface and can present their antigens to T cells (as is also
true for virus-infected cells). However, in the case of tumor cells, MHC class I molecules
are often down-regulated and/or mutated, resulting in T cell anergy or inability to
respond. Thus, it is tempting to speculate that enhanced expression of the Man2bl gene
in the drug plus radiation group may increase the possibility for tumor antigen
presentation.
Increased NF-kB expression has been frequently implicated in carcinogenesis and
tumor progression. In the present study, NF-KB-regulated genes, Csf3 and Tnffsfla, were
up-regulated and Mapk3 was down-regulated in the drug+radiation group when
compared against the radiation only group. Csf3 is granulocyte stimulating factor and is
often down-regulated in tumors. Up-regulation of this gene suggests that MnTE-PyP
caused changes in the tumor that resulted in enhanced production of a factor that can
recruit granulocytes into the tumor mass. Although granulocytes are not considered to be
major players in immune defense against tumors, there is increasing interest in using
these cells, especially neutrophils, as effectors in monoclonal antibody-based
immunotherapy for cancer (van Egmond 2008). Tnfrsfla encodes a “death receptor”
which is a member of the TNF receptor superfamily (also known as CD 120a and TNFR). Cells undergo apoptotic death when TNF-a binds to this receptor; TNF-a, a major
cytokine secreted by macrophages, is well known to inhibit carcinogenesis (Miki &
Eddy, 2002; Nam, et al., 2008). Thus, the enhanced expression of Tnfrsfla suggests that
combined drug+radiation treatment could be beneficial for tumor control. It is of interest
to also point out that immunotherapies that target TNF-a receptors on cancer cells are
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currently under intense investigation (Bremer, de Bruyn, Wajant & Halfrich, 2009).
Mapk3 was down-regulated in both groups that received radiation. Mapk3 expression is
involved in cell cycle progression, cell division and differentiation (Hernandez, Garcia,
Encio, & De Miguel, 2004; Uzgare & Isaacs, 2005; Uzgare, Kaplan, & Greenberg, 2003).
Radiation is known to inhibit cell cycle progression as cells try to repair the resulting
DNA damage. The further down-regulation in Mapk3 along with the up-regulation in
Tnfrsfl a observed in the drug+radiation group versus the radiation only group suggests
that addition of drug decreases the resistance of possibly hypoxic tumors to radiation.
Increased expression in numerous genes encoding proteins of the NF-kB signaling
pathways has been reported in current literature dealing with cancer and its treatment. In
the present study, the addition of MnTE-2-PyP to radiation did not affect the expression
of these genes: Nfkbl, Rela, Tnfsfl4, Relb, Tnfrsfl 0b, Cd40, and Nfkbia. A significantly
increase in the expression of Bel 10 was observed only when MnTE-2-PyP was used with
radiation. Bel 10 expression promotes apoptosis and is involved in antigen presentation to
T cells (Lin & Wang, 2004; Schulze-Luehrmann & Ghosh, 2006). The up-regulation of
BcllO could be indicative of increased apoptosis and potential for enhanced immune
response with combination of drug+radiation. A major effect in treatment with MnTE-2PyP only, was elevation in the expression of C3. C3 encodes complement component 3, a
major protein involved in the complement system that contributes to innate immunity
(Kindt, et al., 2007). Activation of complement via the classical, alternative or lectin
pathways results in cell lysis due to formation of pores in the cytoplasmic membrane.
Cell destruction, in turn, enhances local inflammatory processes and enhanced T and B
cell responses. This up-regulation in C3 expression correlates with our published data
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(Makinde, et al., 2009) (as shown in Chapter 2) that shows increased B cell counts when
MnTE-2-PyP was administered. The up-regulation of genes involved in immune
regulation such in C3, csf2 and csf3, suggest the presence of immune cells in within the
areas of the tumor. Our data consistently demonstrates the role of the immune system in
RM-9 response to MnTE-2-PyP.
Although we report an increase in expression pro-angiogenic genes when MnTE2-PyP was used in combination with radiation versus the radiation only group, our
survival and tumor volume data shows that MnTE-2-PyP does not exacerbate the
response of RM-9 tumors to radiation. Further studies are required in order to determine
the effect of MnTE-2-PyP on radiation response of tumor in regards to angiogenesis and
metastasis.
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CHAPTER FIVE
DISCUSSION
The RM-9 mouse prostate cancer cell line has been extensively evaluated for
pathological and phenotypic characteristics (Thompson, et ah, 2000). It was originally
derived from a ras + myc transformed/wild-type TP53 primary prostate tumor induced in
the Zipras/myc-9-infected C57BL/6 MPR model. Thompson and colleagues investigated
the effects of ras and the ras+myc combination on endogenous p53 expression. They
demonstrated that the ras oncogene alone induced mild hyperplasia along with TP53
mutation, but activated ras and myc together induced carcinoma without mutation in the
p53 protein. These data suggest that expression of both activated ras and myc genes
circumvent the need for TP53 mutation by neutralizing the tumor suppressor activity of
wild-type TP53 (Lu, Park, Thompson, & Lane, 1992; Thompson, et ah, 2000). Ras and
myc are known as proto-oncogenes under normal conditions, he., c-ras and c-myc.
However, when over-expressed or mutated, these genes have been implicated in
carcinogenesis and cancer progression and hence are referred to as oncogenes. Mutations
that result in persistent activation of myc and/or ras can lead to cell transformation and
have frequently been associated with advanced stages of tumors and increased metastasis
in human cancer (Davies, Eaton, France, & Phillips, 1988; Dong, 2006; Harrington,
Spitzweg, Bateman, Morris, & Vile, 2001; Kerbel, Viloria-Petit, Okada, & Rak, 1998;
Okada, et ah, 1998; Thompson, 1990).
The phenotypic and pathological similarity of RM-9 cells to human PCa along
with the advantage of availability of a syngeneic immunocompetent mammalian system
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led to the selection of this model for the in vivo studies as opposed to the other human
PCa models that would require athymic nude mice with a significantly compromised
immune system. In addition, incidence of human PCa growth in immunocompromised
animal models is relatively low.
LNCaP, PC-3 and DU-145 are the most widely used PCa cell lines and have been
extensively characterized (Webber, et al., 1997a, 1997b). Although, they are all human
PCa cell lines of epithelial origin, each of these cell lines have unique characteristics that
could be useful in investigating tumor progression and response to various therapies.
Unlike the LNCaP, both PC-3 and DU-145 PCa cell lines have been reported as
exhibiting resistance to androgens and contain p53 mutations, which have been
associated with disease progression and metastasis. As such, PC-3 and DU-145 PCa
models are often representative of more clinically advanced stages of PCa. LNCaP, on
the other hand, is androgen sensitive and closely representative of human prostate cancer
that would be treated with radiation in patients (Webber, et al., 1997a, 1997b).

Summary of Findings
It has already been established that metalloporphyrin antioxidants can protect
normal tissues against radiation-induced damage (Vujaskovic, et al., 2002). In order to be
clinically relevant, however, they must not protect the cancer. The overall goal of this
study was to evaluate the effects of MnTE-2-PyP on tumor response to radiation and
explore mechanisms responsible for the observed effects.
Our data demonstrate that MnTE-2-PyP does not protect tumor against radiationinduced damage in the RM-9 model system. We show a decrease in tumor volumes
resulting from radiation treatment regardless of drug treatment, with the slowest rate of
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tumor growth occurring in the group treated with both drug and radiation (although
statistical significance was not obtained). Additionally, we report modestly improved
survival before maximum allowed tumor volume was achieved in the groups that
received combination of drug and radiation.
As expected, radiation-treated groups exhibited immunodepressive characteristics
in the blood and spleen leukocyte populations. The depressive effect of radiation on RBC
counts, hemoglobin, hematocrit and increase in RBC distribution width was alleviated in
the groups that received combination treatment, further supporting current literature on
the protective effect of MnTE-2-PyP in normal tissue. This suggests that the drug could
decrease the risk for anemia associated with radiation therapy (Varlotto & Stevenson,
2005). As Th2 type responses have currently been implicated in radiation-induced
fibrosis, the decrease in radiation-induced IL-4 and IL-13 by MnTE-2-PyP, further
suggest that combination of this drug with radiotherapy may decrease the risk for
radiation-induced normal tissue toxicities. In addition, the MnTE-2-PyP-induced decrease
in capacity to produce these two cytokines in the irradiated group could also be indicative
of its potential anti-tumor efficacy, as the inhibition of IL-4 and IL-13 are currently the
focus in a number of anti-tumor immunotherapy studies (Becker, 2006; Conticello, et al.,
2004; Li, et al., 2008; Todaro, et al., 2008).
The role of Th, Tc, and NK cells in tumor regulation and destruction has also been
well established (Cerwenka & Lanier, 2003; Scott, et al., 2008). Our data show that the
group treated with MnTE-2-PyP had elevated levels of all three of these lymphocyte
populations in the spleen compared to the non-treated group, thus reinforcing potential
anti-tumor efficacy of the drug through expansion of immune system cells that are known
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to be capable of tumor cell destruction. The increase in the B cell population and high
IL-2 production by activated T cells in the drug only-treated group, further demonstrates
the possible beneficial effects of MnTE-2-PyP. This is due to the fact that B cells can
secrete antibodies against tumor antigens, as well as other relevant target molecules, and
IL-2 plays an important role in T cell activation. Indeed, a number of antibody
preparations are currently approved by the FDA for treatment of breast, colorectal, and
several other cancer types; IL-2 is approved for treatment of patients with metastatic
melanoma, advanced kidney cancer and cutaneous T cell lymphoma
(http ://www. cancer, org/docroot/home/index. asp).
Modification, suppression and evasion of immune regulation/responsiveness are
well-documented characteristics of tumors. The diminished ability of the immune system
to recognize malignant cells may be due to the down-regulation of tumor-associated
antigens, impairment of antigen presentation, and secretion of immunosuppressive
cytokines (Croci, et al., 2007). As shown in our results, we see an increase in capacity to
secrete IL-1 (3, IL-6, and MCP-1 in mice with untreated RM-9 tumor which correlates
with the fact that inflammation is widely associated with cancer progression (Allavena, et
al., 2008; Lee & Stupans, 2002). We also see six additional cytokines (G-CSF, GM-CSF,
IFN-y, IL10, IP-10, MIP-lcc, and mKC) that were significantly depressed by the presence
of the RM-9 tumor regardless of treatment received. These findings demonstrate the
potent modulatory effects that tumors can have on production of cytokines that regulate
immune defense mechanisms.
Overall, the findings from our in vivo studies demonstrate that MnTE-2-PyP was
not toxic under the conditions used and suggest that administration of the drug together
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with radiotherapy may enhance anti-tumor immune responsiveness and decrease the risk
for radiation-induced depression in at least some bone marrow-derived cell populations.
The data also support a possible cytokine-mediated role for the slowed tumor progression
recently associated with metalloporphyrin antioxidants
In agreement with our in vivo data, the in vitro analyses show that MnTE-2-PyP
did not protect PCa cells against radiation. Furthermore, in LNCaP cells, MnTE-2-PyP
inhibited DNA synthesis and decreased cell viability in a dose-dependent manner. As
LNCaP cells are a close representative of human PCa that would be treated with
radiotherapy in the clinical setting, the in vitro results generated with the LNCaP cell line
are the most relevant.

Conclusions
In addition to its established function in protecting normal tissues from radiation
damage, our data with RM-9 tumors growing in vivo and RM-9 and human PCa cell lines
cultured in vitro support the following conclusions: 1) MnTE-2-PyP does not protect
prostate cancer against radiation-induced damage, 2) treatment of prostate cancer with
radiation and MnTE-2-PyP results in increased radiation-induced apoptosis and increased
radiosensitivity, 3) MnTE-2-PyP may serve to enhance mechanisms that are vital for
effective immune responses against neoplastic cells, 4) MnTE-2-PyP has potential to
slow tumor progression with improved time/dose regimens, and 5) MnTE-2-PyP could
possibly decrease the risk for anemia in patients undergoing radiotherapy.
Overall, our results with MnTE-2PyP are encouraging and warrant further
investigation in order to evaluate its use and the use of other metalloporphyrin
antioxidants to augment radiosensitivity in the clinical setting. A non-toxic drug that
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significantly increases the therapeutic efficacy of radiotherapy could shorten treatment
time and enhance the quality of life for cancer patients.
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